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Introduction  
 
Genetic characteristics and impaired response to 
controlled ovarian stimulation 
 
Standard in vitro fertilization (IVF) protocols are 
characterized by the administration of exogenous follicle 
stimulation hormone (FSH) which is widely adopted 
regimen for controlled ovarian stimulation (COS) in 
normogonadotrophic women. In daily clinical practice, the 
ovarian response to these protocols are optimal in about 
85% of patients, with more than 3 mature oocytes 
recruited. In about 12-15% of cases, however, an initial low 
response is seen, leading to an increase in the daily dose of 
FSH, resulting in a higher total FSH consumption (e.g. 
>2500 IU) (Alviggi et al., 2013). These observations lead to 
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the development of the concept of “hypo-response” to COS 
to identify normogonadotrophic women who have normal 
estimated ovarian reserves but require high amounts of 
FSH to obtain an adequate number of oocytes retrieved (De 
Placido et al., 2005, Ferraretti et al., 2004, Devroey et al., 
2009). These women seem to be distinct from classical 
poor responders because they have normal ovarian reserve, 
but show an unexpected sub-optimal response when 
stimulated with standard regimens. Conversely, specific 
adjustments of classical protocols seem to optimise ovarian 
response (De Placido et al., 2005).  
On the basis of the current literature, it is possible to argue 
that hypo-response could be related to genetic 
characteristics. More specifically, several lines of evidence 
indicate that this clinical condition may be related to 
polymorphisms of the genes of gonadotropins and their 
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receptors (Alviggi et al., 2009b, Alviggi et al., 2013). 
 
Doctoral research: objectives and sessions 
 
The aim of this research project was to exploit the effects 
of polymorphisms of gonadotropins and their receptors on 
ovarian response: 
 The Session A, developed in the first year, is devoted 
to the results of retrospective analysis concerning the 
role of FSH-R receptor polymorphism (rs6166). This 
findings were recently published in a peer review 
journal (Alviggi et al., 2016b). 
 The Session B, developed in the second year, is 
devoted to the results of a prospective analysis in 
which eight polymorphism of gonadotropins and their 
receptors were evaluated. Our findings regarding 
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Italian population were recently published in a peer 
review journal. (Conforti et al., 2017). The preliminary 
results about all population included were recently 
published as a supplement in Human Reproduction 
Journal (Alviggi et al., 2016c). 
 The Session C developed in the third year of research 
is devoted to a Systematic Review and Meta-analysis 
of available worldwide literature data regarding the 
effect of gonadotropin and their receptors 
polymorphism on COS. This analysis includes 33 
studies and involves more than 4,000 observations.  
This systematic review was accepted for submission by 
Human Reproduction Update editorial board which 
represent the most eminent journal in Obstetrics and 
Gynaecology (Journal Citation Reports Thomson 
Reuters)  
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Section A: Unexpected ‘‘Hyporesponse’’ to Controlled 
Ovarian Stimulation is related to polymorphisms of FSH 
Receptor: a retrospective study.  
 
Background 
Recently, the European Society for Human Reproduction and 
Embryology (ESHRE) published criteria for definition of ‘‘poor 
ovarian response’’ to COS in IVF cycles. According to these criteria, 
at least two of the following characteristics should be present to 
meet the definition: advanced maternal age (>40 years) or any 
other risk factor for poor ovarian response; previous poor ovarian 
response (<3oocytes with a conventional stimulation protocol); and 
abnormal ovarian reserve test (Ferraretti et al., 2011). Nevertheless, 
a further subgroup of ‘‘low prognosis’’ patients who do not fit 
neither with these criteria nor with the classical ‘‘normal responder’’ 
profile can be identified. More specifically, it has been reported that 
10% to 15% of young, normogonadotrophic women show 
suboptimal response to standard gonadotropin-releasing hormone 
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(GnRH)-a long protocol (Alviggi et al., 2013). These patients, 
despite an apparently normal ovarian response (namely, the 
recovery of at least 5 oocytes), require higher doses of exogenous 
FSH than expected based on age, anthropometric variables and 
ovarian reserve tests (Alviggi et al., 2011a, Alviggi et al., 2013). We 
suggest the definition of hypo-responders for these patients. 
Indeed, new lines of evidence indicate that this phenomenon could 
be associated with genetic characteristics (Huhtaniemi et al., 1999, 
Alviggi et al., 2015). We recently reported that the frequency of an 
allelic variant of the luteinizing hormone (LH) beta subunit is higher 
in women with a hypo-response to recombinant human FSH (r-
hFSH) than in the general population (Alviggi et al., 2011b, Alviggi 
et al., 2009b, Alviggi et al., 2013). 
This observation is consistent with clinical trials demonstrating that 
recombinant human LH significantly increases both ovarian response 
and implantation rate in hypo-responders to monotherapy with r-
hFSH (Ferraretti et al., 2004, De Placido et al., 2005). However, the 
LH variant has been found in only 32% of IVF candidates with a 
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hypo-response profile. Thus, the pathogenetic mechanism 
underlying the hypo-response to FSH in about two-third of women 
remains to be established. 
Two polymorphisms of the FSH receptor (FSH-R), Thr307/Asn680 
and Ala307/Ser680, have been associated with a higher requirement 
of exogenous gonadotrophins during COS, (Perez Mayorga et al., 
2000, Mohiyiddeen and Nardo, 2010, Yao et al., 2011), suggesting 
higher ovarian threshold compared with wild type. 
The FSH-R is a member of G-protein-coupled receptor which 
mediates FSH intracellular signals through cyclic 
adenosinemonophosphate pathway (Simoni et al., 1997). 
In addition, FSH-R might explain inter-individual differences in 
menstrual pattern. In fact, in homozygotes Ser680/Ser680 of FSH-R, 
a higher ovarian threshold to FSH, a decreased negative feedback of 
luteal secretion to the pituitaryduring the intercycle transition, and 
longer menstrual cycles have been described (Greb et al., 2005b). 
The aim of this study is to explore FSH-R allelic frequency in a 
cohort of young normogonadotrophic patients expected to be ‘‘good 
  
 
 
12 
 
prognosis’’ based on ESHRE criteria, by stratifying the population 
according to r-hFSH consumption and focusing on the impact that 
these polymorphisms may have on COS outcome. 
 
Material and Methods  
This study was conducted at the Outpatient Fertility Unit of the 
Federico II University in Naples, Italy, from October 2011 to April 
2015. 
The clinical management of women included in this study was not 
modified by the investigators, and no adjunctive interventions were 
necessary. In accordance with our internal protocol, upon 
admission, we obtained written informed consent from all patients 
for the use of their data in agreement with privacy protection laws 
(Italian Law 675/96). 
We retrospectively selected 17 normoresponder young patients 
undergoing a standard IVF/ICSI cycle, with at least 5 oocytes 
recovered, who required a cumulative dose of r-FSH >2500 UI 
(group A). A control group was selected (ratio 1:2) among 
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normoresponder young patients undergoing a standard IVF/ICSI 
cycle, with at least 5 oocytes recovered, who required a cumulative 
dose of r-FSH <2500 UI (group B). The enrolment phase was 
concluded when a total number of 42 patients was reached. 
Inclusion criteria were: age <37 years; menstrual cycle lasting 24 to 
35 days (intra-individual variability + 3 days) 6 months before the 
onset of IVF cycle; FSH <11 IU/L, LH <8 IU/L, and prolactin <30 
ng/mL (measured from the 2nd to 4th day of spontaneous 
menstrual cycle); and at least 5 oocytes retrieved for each patient. 
We excluded from the study patients meeting one or more of the 
following criteria: polycystic ovary syndrome (Rotterdam, 2004); 
stage III to IV endometriosis or elevated CA125 (ASRM, 1997, 
Patrelli et al., 2011); autoimmune disorders; and chromosomal 
abnormalities. 
All patients received a standard GnRH agonist-long protocol using 
triptorelin (Decapeptyl 0.1; Ipsen, Italy) at the daily dose of 0.1 mg 
subcutaneously (SC) starting on the 21st day of the cycle preceding 
IVF treatment. Pituitary desensitization was confirmed by 
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transvaginal ultrasound (no evidence of ovarian activity, endometrial 
thickness < 5 mm) and circulating oestradiol assessment (<50 
pg/mL). Patients with pituitary down-regulation started r-hFSH 
treatment (Gonal F; MerckSerono, Rome, Italy); a starting dose of 
225 IU/day SC was administered for the first 4 days of stimulation. 
This dose was reduced to 150 IU/day in women with serum 
oestradiol >160 pg/mL on day 5 of stimulation. If the serum 
oestradiol was <100 pg/mL on day 5, the daily dose was increased 
to 300 IU. Otherwise, the daily dose remained unchanged.  
In all patients, the ovulatory dose of 10,000 IU human chorionic 
gonadotrophin (hCG) was administered intramuscularly (im) in the 
presence of at least 1 follicle reaching a mean diameter of 17 mm. 
All patients received luteal phase supplementation with a daily dose 
of 50 mg progesterone im (Prontogest, IBSA Farmaceutici Italia 
S.r.l., Italy) from the day of oocyte retrieval. Ongoing pregnancy 
rate was defined as the presence of foetal heart activity detected at 
12 weeks of gestation. 
A blood sample was collected from each patient. Genomic DNA was 
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extracted from peripheral blood leukocytes with a Cell Culture DNA 
kit (QIAGEN, Dusseldorf, Germany) according to the manufacturer’s 
instructions. A fragment of the FSH-R gene from exon 10 (from 10D 
to 10G) was amplified by polymerase chain reaction and analyzed by 
electrophoresis on 2% agarose gel. The segment was then 
extracted with phenol chloroform. The purified fragment was 
digested by Bsrl1 (Biolabs, Schwabach, Germany), and fragments 
were analysed by electrophoresis on 2.5% agarose gel. The 
unpurified fragment, indicating homozygosity for Asn, measured 755 
bp. The purified fragment indicating homozygous Ser generated two 
fragments measuring 612 and 143 bp, respectively. The presence 
of all three fragments indicates the status of homozygosity. 
The serum concentrations of oestradiol and LH were measured 
using an enzyme-linked fluorescent assay (Vidas oestradiol and 
Vidas LH II, respectively; Bio Me´rieux SA, Lyon, France). The 
sensitivity of the method, defined as the lowest concentration that is 
significantly different from zero with probability of 95%, was 0.03 
pg/mL for oestradiol and 0.1 IU/L for LH. The coefficient of 
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variations (CVs) of intra- and inter-assay was <8% for both 
oestradiol and LH. Serum levels of FSH were determined by an 
immunoassay based on luminescence (Amerlite FSH Assay; 
Amersham International plc, Amersham). 
 
Statistical Analysis 
We performed a statistical analysis by SPSS software (Chicago, 
Illinois) version 19 for Windows, applying parametric and 
nonparametric tests where appropriate. The Kolmogorov-
Smirnov test was used to assess the normality of distribution. 
Continuous variables were expressed as absolute numbers, 
average ± standard deviation; categorical variables were 
expressed as percentages. The Student t test was adopted to 
determine the effects of stimulation protocols on continuous 
variables and to evaluate the differences between the groups. 
The χ2 test was used to compare categorical data and to assess 
the Hardy-Weinberg equilibrium of FSH-R genotypes. Statistical 
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significance was defined as P values <0.05. 
 
Results 
We retrospectively reviewed the outcome of 42 cycles of IVF 
women. Demographic, anthropometric, and hormonal characteristics 
did not differ significantly between the two groups (Table 1A). The 
duration of infertility status was significantly different among 
patients with higher r-hFSH consumption versus normal responders 
(4.15 ± 1.2 years vs 3.2 ± 0.9, P = 0.0055). Indications for assisted 
reproduction were comparable in both groups (Table 1A). 
Table 2A shows the outcome of assisted reproduction technology 
(ART) cycles in the two groups. The mean number of r-hFSH vials 
(36.3 ± 7.5 vs 28.6 ± 4.5, P = 0.0001) and number of days of 
stimulation (12.7 ± 2.4 days vs 10.8 ± 2.8, P =0.03) were 
significantly lower in the control group (group B). The number of 
oocytes retrieved was significantly lower in group A (7.1 ± 1.5 vs 
9.6 ± 2.4; P = 0.0003). While the average number of embryos 
transferred was significantly higher in group B (2.7 ± 0.4 vs 2.1 ± 
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0.7; P = 0.001). There were no statistically significant differences 
regarding cumulative pregnancy rates, abortion rates, and rates of 
ongoing pregnancy. Serum levels of oestradiol, measured on the 
day of hCG administration, were significantly lower in group A 
(997.8 ± 384.9 pg/mL vs 1749.1 ± 644.4; P =0.0001). 
In group A, the Ser/Ser genotype was identified in 10 (58.8%) 
patients, the Asn/Ser genotype in 4 (23.5%) patients, and the 
Asn/Asn genotype in 3 (17.6%) patients (Table 1A). In group B, the 
Ser/Ser genotype occurred in 5 (20%) patients, Asn/Ser genotype in 
15 (60%) patients, and Asn/Asn genotype in 5 (20%) patients 
(Table 1A). The χ2 analysis revealed that the genotypes were in 
Hardy-Weinberg equilibrium. 
The incidence of Ser/Ser genotype was higher in patients with 
higher r-hFSH consumption (group A) compared to control group 
(group B; P = 0.02). On the contrary, the Asn/Ser genotype was 
more frequent in group B (P = 0.04). 
 
Discussion 
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This study confirms that the FSH-R genotype may interfere with 
physiological responsiveness of the target organ to FSH stimulation. 
The presence of the FSH-R Ser680 variant seems to result in a 
significant decrease in ovarian response to r-hFSH during ART cycles 
and, therefore, in a significant increase in drug consumption. More 
specifically, among patients requiring a higher cumulative dose of r-
hFSH (group A), the expression of Ser/Ser genotype was 
significantly higher compared to the subgroups carrying variants 
Asn/Ser or Asn/Asn of FSH-R (Table 1A). 
Interestingly, our results show that patients with higher r-hFSH 
consumption and FSH-R Ser680 variant carriers have a longer 
infertility condition (Table 1A). From the analysis of these data, we 
could assume that the increased resistance to endogenous FSH, 
observed in FSH-R Ser680 carriers may affect female fertility, 
delaying pregnancy occurrence. As a matter of fact, a higher basal 
level of FSH was detected in hypo-responder group (Table 2A). 
Nonetheless, this hypothesis needs to be confirmed by larger 
population studies. 
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The frequency of FSH-R polymorphism in our study population 
differed from what reported by other authors. We compared our 
results with those published by Perez-Mayorga et al., (Perez 
Mayorga et al., 2000) taking into consideration the ethnic group 
(Caucasian) and the number of patients involved (n = 161). As 
shown in Figure 1A, Perez-Mayorga et al. observed a prevalence of 
26% for Ser/Ser genotype, 45% for heterozygous Asn/Ser, and 
29% for homozygous Asn/Asn, whereas, in our study population, we 
observed a prevalence of 36%, 45%, and 19%, respectively. The 
difference observed in the frequency of FSH-R polymorphism could 
reflect a particular pattern of distribution in the Campania Region. 
Alternatively, it could be due to a major difference in the design of 
the two studies. More specifically, our recruitment was not 
randomized, and we chose patients from a selected pool of women 
affected by reproductive problems. Moreover, 17 of our 42 patients 
showed ‘‘resistance’’ to the protocols of ovarian stimulation, and 10 
of 17 were homozygous carriers of the Ser680 variant. Therefore, 
the selection criteria used for group A patients (i.e., high 
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consumption of r-FSH) may have significantly affected the 
distribution of allelic frequency in the whole study population, which 
could account for the discrepancy between our results and the ones 
by Perez-Mayorga et al. Our results highlight the existence of a 
subgroup of patients (hypo-responders) who require a higher 
cumulative dose of r-hFSH to obtain a reproductive outcome 
compared to normal responders. As a matter of fact, in all our 
patients at least 3 oocytes were retrieved with peak oestradiol levels 
>500 pg/mL; therefore, on the basis of the new criteria, they were 
classified as ‘‘normal responders.’’ However, when the groups A and 
B were analysed based on the cumulative dose of r-hFSH, the 
average number of oocytes retrieved, the serum oestradiol peak and 
the number of embryo replaced were statistically higher in the 
group receiving the lowest cumulative dose of gonadotropin. This 
observation suggests an ‘‘intermediate’’ category of patients which, 
although not fitting the criteria of ‘‘poor responders,’’ still have a 
marked resistance to ovarian stimulation and a less favourable 
prognosis compared to ‘‘normal responders.’’ 
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The association between FSH-R Ser680 variant and ovarian 
resistance to exogenous gonadotropins observed in our study 
complies with a recent meta-analysis that showed a higher 
consumption of exogenous gonadotropins in homozygous carriers of 
Ser680 (Ser/Ser) genotype compared to Asn/Asn variant carriers 
(Yao et al., 2011). The main differences between our study and 
other publications on this topic (Perez Mayorga et al., 2000, De 
Castro et al., 2003, Behre et al., 2005, Loutradis et al., 2006, Genro 
et al., 2012) concern the study design and the parameters 
evaluated. 
In our study, we stratified the population on the basis of 
gonadotrophins consumption rather than on the FSH-R genotype 
expression, in order to identify the mechanism underlying the 
hyporesponse phenomenon. Thus, we were able to identify a 
significant difference in the frequency of Ser/Ser genotype between 
hyporesponder patients and control group (58.8% vs 20.0%). 
Our results disagree with the findings of the Fanchin group (Genro 
et al., 2012), which indicate that follicle-stimulating hormone 
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receptor genotype does not influence antral follicle responsiveness 
to FSH. This important difference may be due to the elevated FSH 
doses (300 UI) used in the Fanchin study that could have overcome 
the lack of functionality of FSH receptor in women carriers of Ser680 
variant. Whereas our decision to use a cumulative r-hFSH dose of 
2500 IU as a cut-off to define the two profiles of response was 
based on our clinical experience, according to which young 
normogonadotrophic women with body mass index <27 kg/m2 
achieve an adequate ovarian response with cumulative doses of FSH 
not exceeding 2000 to 2225 IU. 
Although none of the patients enrolled showed a poor responder 
profile, we observed a decreased number of retrieved oocytes 
(Figure 2A) and transferred embryos in the hypo-responder group, 
in which the incidence of FSH-R Ser680 variant was higher (58.8% 
of cases; Table 1A). A possible effect on ovarian stimulation 
outcome was argued by De Castro et al. (De Castro et al., 2003). 
Specifically, they reported a higher incidence of Ser/Ser carriers 
among poor responder patients in which the number of oocytes 
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retrieved was less than three. Interestingly, we found that the 
homozygous Ser680 variant seems to affect serum oestradiol 
(Figure 3A). In fact, during stimulation, oestradiol levels were lower 
in Ser680 variant carriers than in Asn/Asn ones. This observation is 
in line with another report showing lower serum oestradiol in 
Ser/Ser carriers at the time of hCG administration. As mentioned 
previously, another group of hypo-responder patients was identified 
among common LH variant carriers. This polymorphism is quite 
common with a prevalence estimated around 42% in some 
countries of Northern Europe and is characterized by a reduced in 
vivo bioactivity and low response to r-hFSH. Therapeutic behaviour 
of both v-beta LH and FSH-R polymorphism carriers seems to be 
comparable in terms of cumulative r-hFSH dosage and number of 
oocyte retrieved. Although our results are supported by rigorous 
methods and statistical analysis, they are not free from limitation 
potentially affecting the accuracy of evidences. The relative small 
sample size, in particular of case group, and the retrospective 
design of the study led us to recommend caution in the data 
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interpretation. Certainly, our results require further validation by 
large-scale randomized prospective trials. Although the reduced size 
of our study, 58% (10/17) of patients with a hypo-response profile 
during CO carried FSH-R homozygous Ser680 genotype. Thus, we 
can hypothesize an association between the investigated FSH-R 
polymorphisms and the risk of ovarian resistance to exogenous FSH. 
The fact that the FSH-R genotype affects the ovarian response to 
FSH has implications for the sub-stratification of patients, for the 
choice of stimulation protocol, and for the starting dose of 
gonadotropins. There is increasing evidence that the generic 
definition of the expected ovarian response (poor, normo, and high, 
according to the ovarian reserve test) does not cover all possible 
differences in the general population. Moreover, in the large pool of 
normoresponders patients, great differences remain in terms of 
ovarian responsiveness. In our opinion, the identification of a 
different cohort of patients with an increased or decreased ovarian 
sensitivity to FSH, based on unique genetic patterns (FSH receptor 
polymorphisms), could improve the cost-effectiveness of IVF 
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treatments. Indeed, in case of particular FSH-R polymorphisms 
associated with lower ovarian response, we suggest the choice of a 
higher gonadotropins starting dose and the combination of different 
gonadotropin preparations, for instance by adding recombinant LH 
to standard r-FSH stimulation. This already proved effective also in 
poor-responder patients (Alviggi et al., 2011a, Gizzo et al., 2015, 
Gizzo et al., 2016). It is conceivable that a ‘‘tailored’’ FSH therapy 
may be adopted on the basis of patient genetic profile, customizing 
not only the dosage but also the timing of stimulation. Other 
possible benefits could be the reduction in the stimulation duration 
and the amount of FSH needed. Moreover, the knowledge of the 
mechanisms regulating the ovarian sensitivity to FSH can be useful 
in the prevention of ovarian hyperstimulation syndrome. The 
immediate implications would be saving in costs and increased 
treatment acceptance.  
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Section B:  
 
Background  
Pharmacogenomic approach to ovarian stimulation is attracting an 
increasing interest in reproductive field (Altmäe et al., 2011). 
Currently, COS is guided by clinical history, demographic, 
anthropometric characteristics and ovarian reserve markers such as 
antral follicle count and anti-müllerian hormone. Several lines of 
evidence suggest that individual genotype profile could influence 
COS. In detail, most of researchers focused about the possible 
effect of specific polymorphisms in gonadotropins and 
gonadotropins receptor genes.  
FSH-R polymorphism located in exon 10 in the amino acid position 
680 (FSH-R A680G; rs6166) was the most widely investigated. 
Specifically, women homozygous for FSH-R S680 required higher 
amount of exogenous gonadotropin during COS (Behre et al., 2005, 
Sudo et al., 2002) and showed higher basal FSH levels (Yan et al., 
2013, Perez Mayorga et al., 2000). Furthermore, some authors 
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reported an increased risk of ovarian hyperstimulation syndrome 
(OHSS) syndrome in FSHR S680 homozygous (Daelemans et al., 
2004).  
In addition polymorphism in 5’ untranslated region of FSH-R (FSH-R-
G29A, rs1394205) seem to also affect ovarian response to 
exogenous gonadotropin. In detail, AA homozygotes have a reduced 
number of oocytes retrieved and lower clinical pregnancy rate 
compared with other genotypes (Achrekar et al., 2009a). Another 
study seems to support these finding reporting also a reduced 
number of MII oocytes in subjects with AA genotype comparing with 
GG genotype (Desai et al., 2011). Nonetheless, Tohlob et al. 
reported higher live birth rate in women carrying A allele in a 
retrospective analysis of 603 women who underwent in vitro 
fertilization (Tohlob et al., 2016).  
So far, an increased exogenous FSH consumption in carries of 
genetic variant of LH beta subunit (rs1800447) was also reported 
(Alviggi et al., 2011b, Alviggi et al., 2013). This polymorphism is 
characterized by a reduced half-life in vivo compared with wild type 
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form (Haavisto et al., 1995) and is widely expressed in Northern 
Europe population.  
Luteinizing hormone/human chorionic receptor’s (LHCG-R) 
polymorphisms were also recently investigated. In detail, in a large 
cross sectional study involving 384 IVF women higher pregnancy 
rate was observed in women carrying LHCG-R 312G polymorphism 
compared with A312 carriers (LHCG-R A312G, rs2293275). 
Furthermore, LHCG-R G homozygotes required higher doses of 
exogenous FSH for follicular recruitment versus A homozygotes. 
This polymorphism was also associated with polycystic ovarian 
syndrome (PCOS) with a 2.7-fold increased risk of AA homozygotes 
in Sardinian population (Capalbo et al., 2012) . 
These aforementionated polymorphisms seem also to exert an effect 
on COS when combined. For instance, women homozygous for G in 
both FSH-R A680G and LHCG-R A312G polymorphism showed 
higher pregnancy rate compared with those homozygous for A 
(Lindgren et al., 2016). Furthermore, a retrospective analysis 
demonstrate how homozygotes of both AA FSH-R -29 and AA of 
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FSH-R A680g polymorphism have an increased risk of impaired 
ovarian response following ovarian stimulation (Desai et al., 2013). 
Moreover, presence of both FSH B 211 GT plus FSHR2039 AA 
genotype had a significant reduced day 3 FSH levels compared with 
FSHB-211 GG/FSHR2039 GG genotype.  
Nonetheless, the majority of studies on that issue are based on 
retrospective analysis with relevant selection bias among trials. In 
addition, the heterogeneity in terms of IVF protocols adopted and 
patients recruited makes these results still debateable. Finally, to 
our knowledge the combined effect of polymorphisms was mainly 
studied in retrospective manner involving only a few number of 
polymorphisms.  
The aim of the present multicentre prospective analysis is to 
evaluate the influence of multiple gonadotropin and their receptor 
polymorphisms in women undergoing COS for ART co-treated with a 
GnRHa long down-regulation protocol and fixed FSH starting dose.  
 
Material and methods 
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Study population 
Only Caucasian women have been included adopting the following 
inclusion criteria: Age between 20–35 years; Body Mass Index (BMI) 
between 20–27 Kg/m2; Basal FSH ≤10 IU/l; Indication for IVF 
treatment; presence of both functional ovaries. Exclusion criteria 
were: anomalies of the uterine cavity on both ultrasound and 
hysteroscopy, endocrine, genetic or systemic inflammatory-
immunological disorders, diagnosis of polycystic ovarian syndrome 
according Rotterdam criteria, endometriosis. In addition, women 
with history of more than two previous IVF cycles with normal 
ovarian response or previous stimulation cycle which had been 
cancelled for insufficient ovarian response or in which <4 oocytes 
had been retrieved was excluded. The study was approved by the 
ethical committee board Federico II University, Naples, Italy. 
 
Stimulation protocol 
All patients underwent a GnRH-a long down-regulation protocol with 
buserelin acetate (Suprefact) as follows: 0.5 mg s.c. daily from the 
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mid-luteal phase for 12-14 days, after which the dose was reduced 
to 0.2 mg. After 14 days, transvaginal-ultrasonographic (TV-USG) 
and biochemical evaluations were carried out: only women with 
serum oestradiol level <40 pg/ml, endometrial thickness <5 mm, 
and arrested follicular development were admitted for controlled 
ovarian stimulation. Women with delayed suppression (including 
subjects who develop ovarian cysts after the GnRH-a administration) 
were excluded. A fixed starting-daily dose of 150 of r-hFSH was 
established for all the participant (Gonal-F®; Merck Serono S.p.A, 
Rome, Italy). The starting gonadotropin dose was maintained for 
four days. Oestradiol serum levels was measured on day five of 
stimulation. On that day, the daily dose of gonadotropin was 
modified only in women having oestradiol concentration >180 
pg/ml. Only in these cases, according standard clinical practice, a 
daily dose of r-hFSH of 112.5 IU was adopted. Follicular growth was 
evaluated by on day 8 of stimulation by TV-USG. Only patients who 
displayed at least 6 follicles ranging between 6 and 10 mm, but no 
follicle with a mean diameter >10 mm received an increase in the 
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daily gonadotropin dose. Specifically, the dose of FSH was increased 
by 150 IU per day of r-hFSH, giving a cumulative daily dose of 300 
IU. Women who had their daily dose of gonadotropin reduced on 
the fifth day of stimulation and who required a new increase on day 
8 was excluded from the observation. Analogously, women who 
required “coasting” for reducing the risk for OHSS was not included 
in this study. Oestradiol serum levels were measured on days 1, 5, 8 
of stimulation and on the day of hCG administration. All the other 
determinations, including hormone measurements and 
polymorphism evaluation are described in Table 1. The ovulatory 
dose 10,000 IU of hCG or 250 mcg of recombinant hCG was 
administered in the presence of three follicles with a mean diameter 
of at least 17 mm according to clinical practice. Oocytes was 
retrieved by transvaginal ultrasound-guided aspiration 34-36 h after 
the hCG injection. Serum concentrations of LH was measured on the 
day of pituitary suppression assessment and on the eighth day of 
stimulation.  
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Sampling and polymorphisms analyses 
Blood samples were collected for evaluating the presence of 
different polymorphisms. The venous blood (10 ml) was allowed to 
clot and centrifuged at 400 g for 10 min. Serum was separated, 
divided into a maximum of four aliquots and frozen. Pellets was also 
divided in four aliquots and stocked at -80°C to be successively 
evaluated. The PCR-based Custom TacMan® DNP Genotyping Assay 
(Applied Biosystems) was used to genotype the following eight 
single nucleotide polymorphisms (SNP): (i) FSHR 307 rs6165, (ii) 
FSHR 680 rs6166, (iii) FSHR-29 rs1394205, (iv) LHCGR intronic 
rs4073366, (v) LHCGR 291 rs12470652, (vi) LHCGR rs2293275, (vii) 
FSHB 2623 rs6169, (viii) v-LH rs1800447 
 
Primary and secondary endpoints  
Primary endpoint was the ratio of FSH/oocytes retrieved. Secondary  
endpoint(s): Estradiol levels on the day of hCG; cumulative dosage 
of r-hFSH,  number of preovulatory follicles, mature oocyte retrieved 
(MII oocytes), percentage of mature oocytes; n. oocytes fertilized; 
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number of embryos transferred, days of stimulation, implantation 
rate, pregnancy rate per cycle, pregnancy rate per transfer, clinical 
pregnancy rate for started cycle (presence of embryo with 
heartbeat) clinical pregnancy rate per transfer (presence of embryo 
with heartbeat). 
 
Statistical Analysis 
Genotype frequencies of SNPs evaluated were obtained by direct 
computing, using SNPStats. Linkage disequilibrium was evaluated 
using SNPStat. Hardy-Weinberg equilibrium was evaluated by direct 
computing. Chi-square test was used to compare SNPs frequencies 
of enrolled patients to general population 
(http://hapmap.ncbi.nim.nih.gov). We created genetic models of 
inheritance, comparing the allele frequency to general population. 
Thus according to genotypes frequencies, four models were 
generated: codominant, dominant, recessive and overdominant. 
Dominance in genetics is a relationship between alleles of one gene, 
in which the effect on phenotype of one allele masks the 
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contribution of a second allele at the same locus. Codominance 
occurs when the contributions of both alleles are visible in the 
phenotype. Considering data available in the literature, we 
considered dominant the allele most frequent in the general 
population and we generated these four models starting from these 
observation. 
Kolmogorov-Smirnov test was used for evaluation of variables 
distribution. Differences for continuous variables among groups 
were evaluated performing ANOVA univariate, for parametric 
variables, and Kruskal-Wallis or Mann-Whitney for non-parametric 
ones. Dunnet test was used as post-hoc test. Rho-Sperman’s 
regression was used for correlation. Statistical analysis was 
performed using the ‘Statistical Package for the Social Sciences’ 
software for Macintosh (SPSS Inc version 20.0 USA, Chicago, IL). 
A p value < 0.05 was considered as statistical significant. 
 
Results 
Ninety-four women with a mean age of 30.71 ± 2.61 years and a 
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mean BMI of 22.94 ± 2.35 kg/m2, attending IVF/ICSI cycles were 
enrolled. Genotype distribution of SNPs was consistent with the 
Hardy-Weinberg equilibrium and no differences were seen 
comparing the allele frequencies in the study group to general 
population (Table 1B). 
At baseline, the mean FSH serum levels were 6.75 ± 1.98 IU/L. All 
patients were treated with r-HFSH 150 IU daily, according to the 
study protocol and the mean cumulative r-hFSH dosage used was 
1,725.33 ± 520.15 IU for an average duration of about 11.24 ±1.69 
days (Table 1B). Only one cycles (1.1%) were interrupted for OHSS, 
whereas no cycles were interrupted for absent response to OS. 
After OS, E2 serum levels reached the mean value of 1655.43 ± 
895.59 pg/mL and women under went to IVF in 28.7% of cases (27 
women) and to ICSI in 71.2% of cases (67 women) (Table 2B). 
Forty pregnancies (42.5%) were obtained through the βhCG 
measurement and 32 of these (34.0%) were confirmed at 
ultrasonography evaluation (Table 2B). No differences between 
pregnant and non-pregnant women were found for each parameter 
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considered in the study. 
 
FSHR 307 (rs6165) and FSHR 680 (rs6166)  
The number of total oocytes retrieved was not different considering 
both FSHR rs6165 (p=0.510) and FSHR rs6166 (p=0.170).  
The ratio between total consumption and n of oocytes retrieved was 
significant different among three genotypes (p=0.050), with lower 
ratio in homozigotic A/A compared to homozigotic G/G and 
heterozigotic women. 
The ratio between total consumption and number of oocytes 
retrieved was significant lower in homozigotic G/G compared to both 
homozigotic (A/A) and heterozigotic patients (A/G) (p=0.049). 
Overall, no differences were found in both SNPs considering the 
total r-hFSH dosage used, the ratio between fertilized and 
inseminated oocytes, and other outcomes (Tables 3B and 4B). 
 
FSHR -29 (rs1394205) 
No significant differences with respect of treatment outcomes were 
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found among models generating according to genotypes frequencies 
(Table 5B).  
 
LHCGR 291 (rs12470652) 
LHCGR heterozygous women showed higher E2 levels at the day of 
hCG administration (p=0.005) compared to wild type (Table 6B). 
Similarly, higher number of total oocytes retrieved (p=0.035), MII 
(p=0.002), insemined (p=0.001), fertilised oocytes (p=0.001) and 
cryopreserved embryos (p=0.001) was detected in heterozygous 
compared to wild type (Table 6B). No significant differences among 
other variables were found (Table 6B). 
 
LHCGR intronic (rs4073366), LHCGR 312 (rs2293275), FSHB 2623 
(rs6169) and v-LH (rs1800447) 
No significant differences were found for all parameters considering 
LHCGR rs4073366, LHCGR rs2293275, FSHB rs10835638 and v-LH 
rs1800447. 
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Multivariate analysis 
The overall consideration of the eight SNPs evaluated in the study 
showed that the co-presence of allele G of FSHR -29 rs1394205 and 
allele C of LHCGR 291 rs12470652 was related to an increased ratio 
between cumulative r-hFSH dose and total number of oocytes 
retrieved (5.47, CI 95%:3.13-7.81, p<0.001) (Figure 1B). This 
effect of SNPs on these two genes was confirmed also considering 
the SNP FSHR rs6166. In particular, the co-presence of allele G of 
both FSHR -29 rs1394205 and FSHR rs6166 and allele C LHCGR 291 
rs12470652  were related to an increased ratio between cumulative 
FSH dose and total number of oocytes retrieved (5.44, CI:3.18-7.71, 
p<0.001) (Figure 1B). 
 
Discussion 
For the first time, the simultaneous analysis of eight SNPs was 
carried out in 94 IVF women. By the analysis of our data, emerged a 
significant impact of several SNPs on female reproductive outcome. 
In particular two common SNPs of FSHR (FSHR rs6165 and rs6166) 
  
 
 
41 
 
seem to significantly influence FSH/oocytes ratio (Table 3B, 4B), 
whereas basal E2 levels seem to be associated with LHCGR 291. 
Furthermore, the expression of LHCGR 291 allele C is associated 
with higher number of oocyte retrieved and consequently more 
embryo cryopreserved (Table 6B). 
In addition, multivariate analysis revealed the expression of allele C 
of FSHR -29 (rs1394205), LHCGR 291 (rs12470652) and FSH rs6166 
have showed a significantly relation to the cumulative r-hFSH 
dosage and total number of mature oocyte. 
The possible implication of LHCGR 291 (rs12470652) polymorphism 
on female reproduction was never reported so far. In contrast to 
Ackrekar et al. 2009 (Achrekar et al., 2009b), FSHR -29 
polymorphism alone was not associated with impaired response 
alone. This discrepancy could be due to retrospective design, 
inclusion criteria and heterogeneous protocol adopted by Achrekar 
et al. Conversely, in our study the population included fulfilled strict 
inclusion criteria and was prospectively analysed with a standardized 
ovarian stimulation. Findings regarding polymorphism of FSH-R 
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rs6166 and rs6165 are consistent with those reported in literature 
(De Castro et al., 2003, Yan et al., 2013, Perez Mayorga et al., 
2000). Resistance to FSH in GG carriers of FSHR rs6166 seems to be 
related to specific molecular characteristics (Casarini et al., 2014, 
Casarini et al., 2015). In opposite to our previous studies (Alviggi et 
al., 2011b, Alviggi et al., 2013), we did not observe an association 
between ovarian response and common LH beta polymorphism 
(rs1800447). This incongruity could be explained by the absence of 
homozygous carriers of the variant in this study and the limited 
sample size comparing with those reported in 2013 (Alviggi et al., 
2013). Furthermore, the different study-design could also have been 
crucial for this discrepancy.  
The strength points of our study resided in several aspects. Firstly, 
we have conducted a multicenter prospective analysis of data using 
strict inclusion criteria. Indeed, we have included only good 
prognosis women with established a fixed starting-daily dose 
without any anomalous response during ovarian stimulation. This 
decision was taken considering that the use of higher FSH dosage or 
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adjusting dosage during stimulation could in some mitigate the 
effect of genotype on IVF which represent a common bias reported 
in other studies (Genro et al., 2012). Furthermore we have also 
performed a multivariate analysis with the aim to established 
whether any interaction among different polymorphism is present 
and could influence ovarian response. So fa,r the most of published 
studies focused their attention in single polymorphism (De Castro et 
al., 2003, Achrekar et al., 2009b, Jun et al., 2006, Genro et al., 
2012, Lazaros et al., 2012) and the most recent ones to at least two 
of them (Lindgren et al., 2016, Desai et al., 2013). Furthermore, to 
our knowledge for the first time we provide data about unexplored 
polymorphism such as LHCGR intronic (rs4073366), FSHB 2623 
(rs10835638).  The limitation of our analysis is essentially due to the 
relative small number of patients involved considering the amount of 
polymorphism analysed. Furthermore, we was not able to follow up 
patient until birth, however we provide data about ongoing 
pregnancy rate. As other trials, ours failed to found a significant 
association with pregnancy outcomes. Nonetheless, in our opinion 
  
 
 
44 
 
ART births did not represent the ideal parameter to measure the 
effect of polymorphism. Indeed, various factors such as embryo 
quality, maternal age, some of which occurring during the late 
stages of pregnancy like intrauterine growth restriction transcend 
the “physiological” effects of gonadotropins and their receptors. In 
other words, we sustained that the ovarian response in terms of 
number of oocytes and consumption of gonadotropin represent the 
most appropriate outcomes to address the effects of gonadotropins 
and their receptor polymorphisms in ART. Finally, we only 
considered women who underwent long analogue protocol so we 
cannot provide data about antagonist regimens.  
In conclusion, our study confirmed that specific polymorphism might 
affect ovarian response to ovarian stimulation. In addition we 
demonstrated how a comprehensive evaluation of multiple 
polymorphism could provide useful information about COS response. 
Our data need to be corroborated by further investigations 
especially for other polymorphism in which no sufficient data are still 
present to drawn a definitive conclusion (such as LHCGR intronic 
  
 
 
45 
 
[rs4073366], FSHB 2623 [rs10835638]). The genotype assessment 
in ART could lead to an innovative and individual tailored 
pharmacogenomic approach to ovarian stimulation.   
  
 
 
46 
 
Session C. Clinical relevance of genetic variants of 
gonadotropins and their receptors in controlled ovarian 
stimulation: a systematic review and meta-analysis  
 
Background 
 
 
Ideally, the individual approach for COS in infertile patients who 
seek ART, would involve a comprehensive evaluation of the patient's 
characteristics, including genotype profile.  
Pharmacogenomics evaluates how genes influence individual 
responses to medication. Pharmacogenomic approaches could be a 
cost-effective strategy in several medical fields (Patel et al., 2014, 
Mizzi et al., 2016). Data regarding the clinical utility of 
pharmacogenomics in ART are still scanty (Greb et al., 2005a). 
Nonetheless, increasing evidence indicates that specific genetic 
characteristics of gonadotropins and their receptors could influence 
ovarian response to exogenous gonadotropins. Specifically, a 
common single nucleotide polymorphism (SNP) of the follicle 
stimulating hormone receptor (FSHR, rs6166) was associated with 
increased FSH consumption during COS (Yao et al., 2011). This SNP 
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was also associated with increased FSH basal levels, which suggests 
an impaired response to both endogenous and exogenous 
gonadotropins (Perez Mayorga et al., 2000, Behre et al., 2005, 
Simoni and Casarini, 2014, Alviggi et al., 2016b). Moreover, the 
FSHR polymorphism at position -29 (FSHR, rs1394205) was 
associated with a poor ovarian response (Achrekar et al., 2009b). 
Similarly, a suboptimal response to in IVF was observed in SNP 
carriers of the gene encoding the LH beta subunit (Alviggi et al., 
2011b, Alviggi et al., 2013). Recently, a possible effect of the LH 
receptor SNPs (LHCGR, rs2293275 and LHCGR, rs12470652) on COS 
and ART was also reported (O'Brien et al., 2013, Alviggi et al., 
2016c, Lindgren et al., 2016). Based on this evidence, some authors 
have also hypothesized that a “hypo response” to gonadotropin 
therapy could be explained by specific genotype characteristics. 
Contrary to what is observed for poor-responders, “hypo-
responders” are women with a good prognosis for ART in terms of 
basal characteristics and ovarian reserve but in which a higher than 
expected dose of gonadotropins and more prolonged stimulation are 
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required to obtain an adequate number of oocytes (Alviggi et al., 
2013).  
Given the steady increase in evidence that SNPs affect COS and ART 
outcomes, we conducted a systematic review and meta-analysis 
data in the attempt to summarize the clinical evidence regarding the 
impact of polymorphisms of gonadotropin and their receptors on the 
outcome of COS. 
 
Materials and Methods  
 
Protocol and registration 
This study was exempt from institutional review board approval 
because it did not involve human intervention. We adhered to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. The study protocol was registered at 
http://www.crd.york.ac.uk/PROSPERO/ (registration number 
CRD42016050402) on 31 October 2016, before starting the review 
process. 
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Eligibility criteria  
The selection criteria are described according to PICO (Patients, 
Intervention, Comparison, and Outcomes). We only included women 
who underwent COS, and evaluated COS outcomes according to 
individual genotype expression. 
 
Search strategy  
We conducted a systematic search using the MEDLINE (PubMed), 
EMBASE, SCOPUS, and Cochrane Library databases to identify all 
relevant studies published before January 2017. Combinations of the 
following keywords and MESH search terms were used: “COH”, 
“COS”, “controlled ovarian stimulation” “ART”, “IVF”, “ICSI”, 
“FIVET”, “IUI”, “intrauterine insemination”, “ovulation induction”, 
“polymorphism” OR “SNP” “luteinizing hormone/choriogonadotropin 
receptor” “LHCGR”, “FSH Receptor”, “FSHR”, “FSH”, “follicle 
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stimulating hormone”, “follicle stimulating hormone, beta subunit”, 
LH”, “luteinizing hormone”, “luteinizing hormone, beta subunit”. No 
time or language restrictions were adopted, and queries were 
limited to human studies. The reference lists of relevant reviews and 
articles were also hand-searched.  
 
Selection of studies  
Titles and abstracts were independently evaluated. Duplications 
were removed using Endnote online software and also manually. 
Disagreements were resolved by discussion among authors, and if 
required, with the involvement of the most experienced authors. 
Only clinical trials published in peer-reviewed journals were 
evaluated. Case series, case reports, book chapters, congress 
abstracts, and grey literature were not included. 
 
Data extraction 
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Data were extracted independently using predefined data fields, and 
study quality indicators. Discrepancies were resolved by discussion 
with the senior authors. 
 
Risk of bias, summary measures and synthesis of the results 
The risk of bias and quality assessment of the included studies were 
performed using the Newcastle-Ottawa Scale (NOS) (Wells et al., 
2004). Two authors independently assessed the risk bias for each 
study. The senior authors resolved conflicts. The NOS score was 
used to evaluate the studies included, and judgement on each one 
was passed according to three issues: selection of the study group, 
comparability between groups, and ascertainment of exposed/not 
exposed cohorts.  
The primary outcome was the number of oocytes retrieved. 
Secondary outcomes were: FSH consumption, stimulation duration 
(number of days of gonadotropin use for COS), ratio between FSH 
consumption (total dosage of exogenous gonadotropin used) and 
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the number of oocytes retrieved, the number of metaphase II 
oocytes, and ongoing pregnancy rate (OPR). The latter was defined 
as a pregnancy diagnosed by ultrasonographic visualization of at 
least one gestational sac. Bias across studies regarding the primary 
outcome was assessed using visual inspection of funnel plots, and 
the trim and fill method (Duval, 2006) and the Egger test (Egger et 
al., 1997). 
 
Quantitative analysis  
Statistical analysis was carried out using Review Manager 5.3 (The 
Nordic Cochrane Centre, The Cochrane Collaboration). Categorical 
data were combined with a pooled odds ratio (OR) using the 
Mantel-Haenszel method. Continuous data were combined with 
weight mean differences (WMD) using the inverse variance method. 
Only when at least 3 or more studies were available, a meta-
analysis was conducted using the fixed-effect-model (FEM) or the 
random effect model (REM). REM was used in the case of significant 
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heterogeneity among studies. Heterogeneity was assessed using the 
percentage of total variation in the estimated effect across studies 
(I2). An I2 value > 50% indicates substantial heterogeneity. P 
values < 0.05 were considered statistically significant. A post-hoc 
estimation of the ratio between FSH consumption and the number 
of oocytes retrieved was carried out when three or more studies 
were available.  
Subgroup analysis  
Subgroup analysis by type of exogenous FSH (i.e., recombinant 
versus urinary), was conducted to assess potential sources of 
heterogeneity for FSH/oocytes ratio and number of oocytes 
retrieved. Sensitivity analysis was carried out to assess the leverage 
of studies with low risk of bias (NOS ≥ 6) on the results. 
 
Results  
 
Study selection and study characteristics 
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A total 1,051 items were identified from the databases (Figure 1C). 
After removing 167 duplicates using Endnote software (EndNote X 
6.0.1, California State University) and 45 duplicates manually, 
abstracts and titles of 839 papers were scrutinized. Hand search of 
reference lists of relevant reviews were used to complement 
database searches. Overall, 59 articles were assessed for eligibility. 
Fifteen articles were excluded because they did not fulfill inclusion 
criteria. Data extraction was not possible in 10 articles (Daelemans 
et al., 2004, De Castro et al., 2004, D'Alva et al., 2005, Livshyts et 
al., 2009, Lazaros et al., 2012, Boudjenah et al., 2014, Colognato et 
al., 2014, Almawi et al., 2015, Laisk-Podar et al., 2015, Valkenburg 
et al., 2015), because COS and ART were not evaluated on the basis 
of polymorphism genotype expression. Data duplication was 
detected in studies by Desai et al. (Desai et al., 2013, Desai et al., 
2011) and by Mohiyiddeen and collaborators (Mohiyiddeen et al., 
2013a, Mohiyiddeen et al., 2013b). The following studies were 
included in our analysis (Desai et al., 2011, Mohiyiddeen et al., 
2013b). Of note, we only extracted data regarding MII oocytes from 
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Mohiyiddeen et al. 2013a that were not reported in their subsequent 
paper (Mohiyiddeen et al., 2013a). Thirty-three studies were 
included in our quantitative and qualitative analysis (Figure 1C and 
Table IC). Seven polymorphisms were reported in these studies: 
FSHR 919 G>A (rs6165), FSHR 2039 G>A (rs6166), FSHR -29 G>A 
(rs1394205), LHB 82 T>C (rs1800447), LHB 1502 G>A (rs1056917), 
LHCGR 935 A>G (rs2293275), LHCGR 3442-25260 A>G 
(rs13405728).  
 
Risk of bias within studies 
Bias assessment within studies is shown in Table IC. A high rate of 
agreement evaluated by k-Cohen calculation, was observed between 
the authors (k-Cohen = 0.83). 
 
Summary of results  
The results of the quantitative analysis of each outcome measure 
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according to genotype distribution are reported below and 
summarized in Table 2C. 
 
FSH consumption 
A meta-analytic approach was possible only for FSHR (rs6165), 
FSHR (rs6166), FSHR (rs1394205). No data were found regarding 
LHB (rs1056917).  
Four studies (Laven et al., 2003, Achrekar et al., 2009a, Genro et 
al., 2012, Yan et al., 2013) for a total of 729 women, evaluated FSH 
consumption in relation to the FSHR (rs6165) genotype distribution. 
FSH consumption did not differ statistically among FSHR (rs6165) 
AA homozygotes, GG homozygotes (Random WMD: 227.64 IU, 95% 
CI: -452.95 to 908.22 IU, I2 = 96%), and AG heterozygotes 
(Random WMD: 110.24 IU, 95% CI: -323.57 to 544.05 IU, I2 = 
93%). Similarly, FSH consumption did not differ between GG 
homozygotes and AG heterozygotes (Random WMD: 134.09 IU, 
95% CI: -162.06 to 430.25, I2 = 81%).  
  
 
 
57 
 
Eighteen studies (Perez Mayorga et al., 2000, Sudo et al., 2002, 
Laven et al., 2003, Behre et al., 2005, Jun et al., 2006, Loutradis et 
al., 2006, Achrekar et al., 2009a, Huang et al., 2010, Nordhoff et 
al., 2011, Sheikhha et al., 2011, Anagnostou et al., 2012, Genro et 
al., 2012, Lledo et al., 2013, Mohiyiddeen et al., 2013b, Yan et al., 
2013, Huang et al., 2015, Lindgren et al., 2016, Lledó et al., 2016), 
for a total of  4,094 women, evaluated FSH consumption according 
to FSHR (rs6166) genotype distribution. FSH consumption in FSHR 
AA homozygotes was comparable to that in GG homozygotes 
(Random WMD: -158.50 IU, 95% CI: -338.32 to 21.32 IU, I2 = 
96%) and AG heterozygotes (Random WMD: 18.00 IU, 95% CI: -
119.36 to 155.35 IU, I2 = 96%). Similarly, no differences were 
found between FSHR GG homozygotes and AG heterozygotes 
(Random WMD: -137.53 IU, 95% CI:-293.04 to 17.97 IU, I2 = 
86%). 
 Three studies (Achrekar et al., 2009b, Desai et al., 2011, 
Tohlob et al., 2016) including 709 women, evaluated FSH 
consumption according to the FSHR (rs1394205) genotype. The 
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consumption of FSH was significantly lower in FSHR GG 
homozygotes than in FSHR AA homozygotes (Random WMD: -
1294.61 IU, 95% CI: -1996.14 to -593.08, P < 0.001, I2 = 99%); 
however, no differences were observed between GG and AG 
heterozygotes (Random WMD: -277.84 IU, 95% CI: -1145.28 IU to 
589.60, I2 = 100%). FSH consumption was lower in AG 
heterozygotes than in FSHR AA homozygotes (Random WMD: -
1014.36 IU, 95% CI: -1664.61 to -364.11, P = 0.002, I2 = 99%) 
(Figure 2C). 
Two studies (Alviggi et al., 2011b, Alviggi et al., 2013) reported FSH 
consumption according to LHB (rs1800447) genotype distribution. 
Both showed significantly higher FSH consumption in variant carriers 
compared with wild-type carriers. 
One study (Lindgren et al., 2016) reported FSH consumption in 
relation to the distribution of the LHCGR SNP (rs2293275) genotype. 
No significant differences among genotypes were detected.  
One study (Yin et al., 2015) reported FSH consumption in relation to 
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the distribution of the LHCGR (rs13405728) genotype. No significant 
differences among genotypes were reported. 
The overall effect estimated by the analyses indicated that FSH 
consumption was only affected by the presence of FSHR 
(rs1394205), which was significantly higher in AA carriers. However, 
these results may be conservative given the high heterogeneity and 
the relatively small number of patients evaluated. 
 
Stimulation duration  
A meta-analytic approach was possible only for FSHR (rs6165), 
FSHR (rs6166), and FSHR (rs1394205). No data were found 
regarding the other polymorphisms. 
Three studies (Laven et al., 2003, Genro et al., 2012, Yan et al., 
2013) for a total of 679 patients, evaluated stimulation duration in 
relation to the distribution of the FSHR (rs6165) genotype. The 
length of stimulation did not differ between FSHR AA homozygotes 
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and GG homozygotes (Random WMD: -0.59, 95% CI: -1.24 to 0.05, 
I2 = 60%), however it was significantly shorter than in AG 
heterozygotes (Fixed WMD: -0.48, 95% CI: -0.87 to -0.10, P = 0.01, 
I2 = 44%). On the contrary, stimulation duration did not differ 
between FSHR GG homozygotes and AG heterozygotes (Fixed WMD 
-0.29, 95% CI: -0.95 to 0.37, I2 = 0%) (Figure 3C). 
 Fifteen studies (De Castro et al., 2003, Laven et al., 2003, 
Behre et al., 2005, Klinkert et al., 2006, Huang et al., 2010, 
Nordhoff et al., 2011, Genro et al., 2012, Lledo et al., 2013, Yan et 
al., 2013, Zalewski et al., 2013, Huang et al., 2015, Alviggi et al., 
2016b, Loutradis et al., 2006) that included 3,069 women, 
evaluated stimulation duration in relation to the distribution of the 
FSHR (rs6166) genotype. The duration of stimulation did not differ  
among FSHR AA homozygotes, GG homozygotes (Fixed WMD: -
0.01, 95% CI: -0.16 to 0.14 days, I2 = 17%) and AG heterozygotes 
(Random WMD: -0.01, 95% CI: -0.04 to 0.05, I2 = 27%). Lastly, no 
differences were observed between FSHR GG homozygotes and 
FSHR AG heterozygotes (Fixed WMD: -0.12, 95% CI: -0.29 to 0.04, 
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I2 = 2%).  
 In summary, the only difference in stimulation duration was a 
shorter duration in in FSHR (rs6165) AA homozygotes than  in AG 
heterozygotes.  
 
Number of oocytes retrieved  
A meta-analytic approach was possible only for FSHR (rs6165), 
FSHR (rs6166), and FSHR (rs1394205). No data were found 
regarding LHCGR (rs2293275).  
 Five studies (Achrekar et al., 2009a, Genro et al., 2012, 
Lazaros et al., 2013, Yan et al., 2013, Trevisan et al., 2014) 
including 1,020 women, reported the number of oocytes retrieved in 
relation to the distribution of the FSHR (rs6165) genotype. The 
number of oocytes retrieved was significantly higher in AA 
homozygotes than in GG homozygotes (Fixed WMD: 1.85, 95% CI: 
0.85 to 2.85, P < 0.001, I2 = 0%) and in AG heterozygotes 
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(Random WMD: 1.62, 95% CI: 0.28 to 2.95, P = 0.02, I2 = 56%). 
No difference was detected between GG homozygotes and AG 
heterozygotes (Fixed WMD: -0.37, 95% CI: -1.51 to 0.78, I2 = 
18%) (Figure 4C). 
 Twenty-one studies (Perez Mayorga et al., 2000, Sudo et al., 
2002, De Castro et al., 2003, Behre et al., 2005, Jun et al., 2006, 
Klinkert et al., 2006, Loutradis et al., 2006, Achrekar et al., 2009a, 
Huang et al., 2010, Nordhoff et al., 2011, Sheikhha et al., 2011, 
Genro et al., 2012, Lazaros et al., 2013, Lledo et al., 2013, 
Mohiyiddeen et al., 2013b, Yan et al., 2013, Zalewski et al., 2013, 
Trevisan et al., 2014, Huang et al., 2015, Alviggi et al., 2016b, Lledó 
et al., 2016) including 4,425 women, reported the number of 
oocytes retrieved in relation to the distribution of the FSHR (rs6166) 
genotype. The number of oocytes retrieved was significantly higher 
in AA homozygotes than in GG homozygotes (Random WMD: 0.84, 
95% CI: 0.19 to 1.49, P = 0.01, I2 = 76%), but it was similar to AG 
heterozygotes (Random WMD: -0.18, 95% CI: -0.84 to 0.48, I2 = 
85%). Significantly higher number of oocytes were found in AG 
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heterozygotes than in GG homozygotes (Random WMD: 0.92, 95% 
CI: 0.18 to 1.66, P = 0.020, I2 = 75%) (Figure 5C). 
 Three studies (Achrekar et al., 2009b, Desai et al., 2011, 
Tohlob et al., 2016) including 709 women, evaluated the number of 
oocytes retrieved in relation to the distribution of the FSHR 
(rs1394205) genotype. The number of oocytes retrieved was lower 
but not significantly different between FSHR (rs1394205) AA 
homozygotes and both GG homozygotes (Random WMD: -5.20, 
95% CI: -11.22 to 0.82, I2 = 99%) and AG heterozygous (Random 
WMD: -3.88, 95% CI: -7.93 to 0.18, I2 = 98%). No differences 
were observed between GG homozygotes and AG heterozygotes 
(Random WMD: -1.29, 95% CI: -3.51 to 0.93, I2 = 97%). 
Only two studies (Alviggi et al., 2011b, Alviggi et al., 2013) reported 
the number of oocytes retrieved considering the LHB (rs1800447) 
genotype. In both studies, the authors did not observed a significant 
difference regarding the number of oocytes retrieved among 
genotypes.  
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Only one study (Davar et al., 2014) reported the number of oocytes 
retrieved considering the LHB (rs1056917) and no significant 
difference among genotypes was observed.  
Only one study (Yin et al., 2015) reported the number of oocytes 
retrieved according to LHCGR (rs13405728) genotype distribution; 
no significant differences among genotypes were detected. 
The overall effect estimated by the analyses indicated that both the 
FSHR (rs6165) and FSHR (rs6166) genotypes impacted on the 
number of retrieved oocytes. In both polymorphisms, AA 
homozygote was associated with an increased number of oocytes 
retrieved, whereas GG homozygote had an opposite effect. Due to 
high heterogeneity, the effect size estimated for the FSHR (rs6166) 
may be conservative. 
 
Number of metaphase II oocytes 
A meta-analytic approach was possible only for FSHR (rs6166). No 
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data were found regarding LHB (rs1056917).  
Only two studies (Genro et al., 2012, Trevisan et al., 2014) 
evaluated the number of MII oocytes retrieved considering FSHR 
(rs6165). In both studies, there was no difference in the number of 
MII oocytes among genotypes. 
 Five studies (Genro et al., 2012, Mohiyiddeen et al., 2013a, 
Trevisan et al., 2014, Lindgren et al., 2016) including 1,185 
patients, reported the number of oocytes MII retrieved in relation to 
the distribution of the FSHR (rs6166) genotype. The number of MII 
oocytes was significantly higher in AA homozygotes than GG 
homozygotes (Fixed WMD: 1.03, 95% CI: 0.01 to 2.05, P = 0.050, 
I2 = 0%). On the contrary, no significant differences were observed 
between AA homozygotes and AG heterozygotes (Fixed WMD: 0.79, 
95% CI: -0-05 to 1.62, I2 = 0%), or between GG homozygous and 
AG heterozygous (Fixed WMD: 0.34, 95% CI: -0.57 to 1.26, I2 = 
49%) (Figure 6C). 
 Only two studies (Desai et al., 2011, Dan et al., 2015) 
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reported the MII oocytes number considering the FSHR 
(rs1394205). In detail, Dan et al. observed a significantly higher 
number of MII oocytes in GG comparing with AG/AA carriers. In the 
same line, findings by Desai et al. showed significantly higher 
number of MII oocytes in GG than AG and AA groups. 
Only one study (Alviggi et al., 2013) reported the number of MII 
oocytes retrieved considering the LHB (rs1800447); no significant 
difference was found between wild-type and variant carriers.  
Only one study (Lindgren et al., 2016) reported the number of MII 
oocytes retrieved considering the LHCGR (rs 2293275); likewise, no 
significant difference among haplotypes was identified.  
Only one study, (Yin et al., 2015) reported number of MII oocytes 
retrieved according to LHCGR (rs13405728) genotype distribution; 
no significant differences among genotypes were detected. 
The overall effect size estimated by the analyses indicates a possible 
negative influence of the FSHR (rs6166) GG homozygote genotype 
on the number of mature oocytes. Due to the limited number of 
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studies and the P levels of exactly 0.05, these results should be 
taken with caution. 
 
Ratio between FSH consumption and number of oocytes retrieved 
A meta-analytic approach was possible for FSHR (rs6165), FSHR 
(rs6166), FSHR (rs1394205). Calculation of FSH dosage/n. oocytes 
ratio was not carried out for LHB (rs1800447), LHB (rs1056917), 
LHCGR (rs2293275), and LHCGR (rs13405728). 
In three studies (Achrekar et al., 2009a, Genro et al., 2012, Yan et 
al., 2013) including 581 women, we calculated the FSH 
consumption/oocyte ratio in relation to the distribution of the FSHR 
(rs6165) genotype. This ratio was significantly lower in AA 
homozygotes than GG homozygotes (Fixed WMD -24.06, 95% CI: -
47.28 - 0.84, P = 0.040, I2 = 50%). On the contrary, no differences 
were found between AA homozygotes and AG heterozygotes 
(Random WMD: -24.31, 95% CI: -65.37 to 16.75, I2 = 58%), or 
between GG homozygotes and AG heterozygotes (Random WMD: 
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14.05, 95% CI: -39.59 to 67.69, I2 = 73%) (Figure 7C). 
 
In 16 studies (Perez Mayorga et al., 2000, Sudo et al., 2002, Behre 
et al., 2005, Jun et al., 2006, Loutradis et al., 2006, Achrekar et al., 
2009a, Huang et al., 2010, Nordhoff et al., 2011, Sheikhha et al., 
2011, Genro et al., 2012, Lledo et al., 2013, Mohiyiddeen et al., 
2013b, Yan et al., 2013, Huang et al., 2015, Alviggi et al., 2016b, 
Lledó et al., 2016) including 3,729 patients, we calculated the FSH 
consumption/oocyte ratio in relation to the distribution of the FSHR 
(rs6166) genotype. This ratio was significantly lower in AA 
homozygotes than GG homozygotes (Random WMD: -41.96, 95% 
CI: -82.90 to -1.03, P = 0.04, I2 = 93%). On the contrary, no 
difference was observed between AA homozygotes and AG 
heterozygous (Random WMD: -9.71, 95% CI: -37.41 to 17.99, I2 = 
93%). The AG heterozygotes showed a significantly lower FSH/n. 
oocytes ratio than GG homozygotes (Random WMD: -34.75, 95% 
CI: -60.19 to -9.30, P = 0.007, I2 = 86%) (Figure 8C). 
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The same approach was used for FSHR (rs1394205) genotype 
distribution. This analysis included three studies (Achrekar et al., 
2009b, Desai et al., 2011, Tohlob et al., 2016) and 709 patients. No 
difference was observed between AA homozygotes and both GG 
homozygotes (Random: WMD: 219.27, 95% CI: -66.11 to 504.65, 
I2 = 95%), and AG heterozygotes (Random: WMD: 217.72, 95% 
CI: -20.63 to 456.07, I2 = 92%). No significant differences were 
detected between GG homozygotes and AG heterozygotes 
(Random: WMD: -4.93, 95% CI: -78.01 to 68.15, I2 = 84%). 
The overall effect estimated by the analyses indicated that both 
FSHR (rs6165) and FSHR (rs6166) genotype impacted on the ratio 
between FSH consumption and the number of retrieved oocytes. In 
both cases, the presence of GG haplotype is associated with ovarian 
resistance to exogenous FSH stimulation. Due to high heterogeneity, 
the effect size estimated for the FSHR (rs6166) may be 
conservative. 
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Ongoing pregnancy rate 
A meta-analytic approach was possible only for FSHR (rs6166). No 
data were found regarding FSHR (rs6165), LHB (rs1056917) and 
LHCGR (rs13405728). 
Seven studies (Jun et al., 2006, Sheikhha et al., 2011, Lledo et al., 
2013, Mohiyiddeen et al., 2013b, Huang et al., 2015, Alviggi et al., 
2016b, Lindgren et al., 2016) including 3,191 patients, evaluated 
OPR in relation to the distribution of the FSHR (rs6166) genotype. 
The overall OR was not different between AA homozygotes and both 
GG homozygotes (Fixed OR: 0.89, 95% CI: 0.70 to 1.12, I2 = 0%) 
and AG heterozygotes (Fixed OR: 0.97, 95% CI: 0.82 to 1.16, I2 = 
29%). Moreover, no significant differences were observed 
comparing GG homozygotes and AG heterozygotes (Fixed OR: 0.95, 
95% CI: 0.77 to 1.18, I2 = 0%). 
Only two studies (Achrekar et al., 2009b, Tohlob et al., 
2016)(Achrekar et al., 2009b, Tohlob et al., 2016) reported OPR 
considering FSHR (rs1394205). Achrekar et al. reported comparable 
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OPR among GG, AG and AA whereas Tohlob et al. observed that 
women carrying the A allele had higher OPR than G carriers (OR 
1.32, 95% CI 1.01 – 1.74, P = 0.04), albeit this association was not 
significant considering the number of embryos transferred.  
Only one study (Alviggi et al., 2013) reported OPR with regards to 
LHB (rs1800447); this study reported no differences between wild-
type and variant carriers.  
Only one study (Lindgren et al., 2016) reported OPR considering the 
LHCGR (rs2293275). Differences in terms of OPR were observed 
among haplotypes (AA: 18%; AG: 27%; GG: 31%, P = 0.037), with 
higher prevalence in GG carriers.  
 
Risk of bias across studies 
We found no significant risk of bias across studies regarding the 
primary outcome adopting Egger’s test (P = 0.828 for FSHR rs6166; 
P = 0.27 for FSHR rs6166, and P = 0.12 for FSHR rs1394205), 
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visual inspection of the funnel plots, and trim and fill method (Figure 
9C).  
 
Subgroup and sensitivity analyses  
We estimated ratio between FSH consumption and number of 
oocytes retrieved according to type of gonadotropin, namely 
recombinant versus urinary FSH (Figure 10-11C). We did not include 
papers in which both gonadotropin have been used for COS  (Behre 
et al., 2005, Jun et al., 2006, Huang et al., 2010, Sheikhha et al., 
2011, Mohiyiddeen et al., 2013b) or in which the formulation 
adopted was not clearly stated (Achrekar et al., 2009a). 
The overall FSH/oocyte ratio was significantly lower in FSHR 
(rs6166) AA homozygotes than GG homozygotes (Recombinant 
Fixed WMD -44.32, 95% CI -65.14 to -23.49, P < 0.0001, I2 = 
14%; extractive Fixed WMD -18.83, 95% CI -35.23 to -2.42, P = 
0.02, I2 = 30%) regardless of the type of gonadotropin used. On 
the other hand, a higher number of oocytes retrieved was observed 
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in AA than GG carriers when recombinant FSH was used (Fixed 
WMD 1.13, 95% CI 0.51 to 1.75, P = 0.0003, I2 = 44%); this 
outcome was not different when extractive gonadotropin was 
adopted (Random WMD 0.68, 95% CI: -2.19 to 3.54; I2 = 86%). 
Sensitivity analysis revealed that the observed pooled effect sizes 
were materially affected with regards to the number of retrieved 
oocytes between FSHR (rs6165) AA and AG carriers. 
Discussion 
 
We conducted this systematic review to unravel the role of 
gonadotropins and their receptors polymorphisms in the outcome of 
COS. We evaluated OPR rather than live-birth rate, because of the 
many confounders that may condition later stages of pregnancy, 
which in turns renders the impact of folliculogenesis-related 
polymorphisms questionable. Our findings indicate that FSH receptor 
polymorphisms affect the outcome of COS. In particular, FSH 
consumption was higher in A allele homozygous carriers of the FSHR 
(rs1394205) genotype. Furthermore, the number of oocytes 
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retrieved was significantly higher in FSHR (rs6165) AA carriers and, 
moreover, stimulation was significantly shorter in these patients 
than in GG and AG carriers.  Along the same lines, FSHR (rs6166) 
AA homozygotes had a significantly higher number of both retrieved 
and mature oocytes than carriers of other haplotypes. Therefore, 
both FSHR (rs6165) and FSHR (rs6166) GG homozygotes seem to 
be less responsive to COS treatment than AA and AG carriers. 
Gonadotropin type did not seem to affect the FSH 
consumption/oocytes ratio in FSHR (rs6166) haplotypes, but could 
affect the number of oocytes retrieved. Notably, the number of 
oocytes retrieved was significantly higher in AA carriers than in GG 
carriers when recombinant FSH was used. The FSHR (rs6166) 
genotype did not significantly affect the ongoing pregnancies rate. 
Our results are consistent with previous reviews (Altmäe et al., 
2011) However, here we used a quantitative approach to determine 
the impact of polymorphisms of gonadotropins and their receptors 
on the main outcomes of COS. It remains to be determined whether 
a pharmacogenomic approach could counteract the effect of such 
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polymorphisms. Only one trial partially addressed this issue (Behre 
et al., 2005). In particular, in this study, normogonadotropic 
patients were stratified according the FSHR (rs6166) haplotype. The 
authors showed that an FSH daily dose of 150 IU resulted in 
significantly lower levels of estradiol in GG carriers than in AA 
carriers. Increasing the FSH dose from 150 to 225 IU/day 
counteracted the lower oestradiol levels in GG carriers. 
Regarding LH polymorphisms, it has been reported that C allele 
carriers of the LHB (rs1800447) variant require higher FSH 
consumption (Alviggi et al., 2011b, Alviggi et al., 2013) than T 
carriers. Moreover, a higher ongoing pregnancy rate has been 
reported in G allele carriers of the LHCGR polymorphism 
(rs2293275) (Lindgren et al., 2016). However, given the paucity of 
data regarding the two aforementioned polymorphisms, we were 
unable to carry out a meta-analysis.  
To sum up, we demonstrate that specific polymorphisms of 
gonadotropins and their receptors could modulate the ovarian 
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response to exogenous FSH. On the other hand, further studies are 
necessary to evaluate the impact on OPR and live birth rate. 
Nonetheless, it should be considered that ART births are strongly 
influenced by various factors, most of which occur during the late 
stages of pregnancy and transcend the “physiological” effects of 
gonadotropins and their receptors. In other words, we maintain that 
the effects of gonadotropins and their receptor polymorphisms in 
ART should be more thoroughly evaluated in terms of ovarian 
response and, more cautiously, at the early stages of pregnancy. 
  
Interpretation of results and clinical considerations 
Our findings could be related to the molecular characteristics of the 
genotypes associated with the COS response (Table III). The FSHR 
gene carries more than 2000 SNPs, although only FSHR (rs6165) 
and FSHR (rs6166) seem to play a prominent role in the COS 
response. Both SNPs cause an amino acid exchange: in FSHR 
(rs6166) asparagine is substituted by serine thereby introducing a 
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potential phosphorylation site whereas in FSHR (rs6165) threonine is 
substituted by alanine, which results in a change from a polar to a 
nonpolar hydrophobic amino acid and thereby removing a potential 
O-linked glycosylation site. These genotypes are in nearly complete 
linkage disequilibrium, except in some African populations (Simoni 
and Casarini, 2014, Casarini et al., 2015). In vitro studies conducted 
using human granulosa cells showed that GG carriers of the FSHR 
(rs6166) genotype have greater resistance to FSH than AA carriers 
(Casarini et al., 2014, Casarini et al., 2015). Our results corroborate 
these observations, since we found that GG carriers require higher 
doses of FSH per oocyte retrieved than AA carriers. Furthermore, 
these carriers showed also fewer oocytes at the end of stimulation 
compared with the other FSHR (rs6166) haplotypes. In these 
women, FSHR resistance to endogenous FSH was also reported 
(Mohiyiddeen and Nardo, 2010). This effect is modulated in both 
man and women by another polymorphism of the FSH beta subunit 
(FSHB, rs10835638) (Grigorova et al., 2010, Ferlin et al., 2011, La 
Marca et al., 2013) which is significantly correlated with the FSH 
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beta subunit transcriptional activity and metabolism (Hoogendoorn 
et al., 2003). There is also evidence that FSHR (rs6166) could 
interact with other polymorphisms that influence ART outcomes. 
Indeed, in a large cohort study, FSHR (rs6166) and LHCGR 
(rs2293275) allele G carriers had a 4-fold increased chance of 
pregnancy versus A carriers of both polymorphisms. Moreover, the 
number of mature oocytes was significantly higher in subjects with 
both FSHR (rs1394205) GG plus FSHR (rs6166) AA genotypes than 
in other genotype combinations of the same polymorphisms (Desai 
et al., 2013). 
The FSHR (rs1394205) polymorphism located in the 50-untranslated 
region of the gene has been extensively studied in association with 
ovarian response. The transcription activity of the  FSHR 
(rs1394205) A allele is lower than that of the G allele (Nakayama et 
al., 2006). Moreover, the expression of FSHR and protein levels is 
also significantly lower in FSHR (rs1394205) AA homozygotes than 
in other haplotypes, thus suggesting that A allele expression is 
associated with ovarian resistance to COS (Desai et al., 2011). This 
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means that FSHR (rs1394205) AA carriers are expected to have a 
higher FSH consumption than GG and AG haplotypes, and therefore, 
need more costly treatment to achieve a comparable number of 
oocytes.  
 
Limitations and strengths 
Like all meta-analyses, our study has several limitations. First, most 
of the studies included were observational and retrospective, and 
thus more prone to bias. Second, the number of studies evaluating 
COS outcomes in relation to the patient’s gonadotropin receptor 
genotype, is relatively small. Third, high heterogeneity among the 
studies included was observed. This could be probably explained by 
the wide variation in terms of population and treatment strategies. 
Lastly, OPRs were inconsistently reported in the included studies, 
however, we were able to conduct a meta-analysis for OPR with 
regards to the FSHR (rs6166), involving an elevated number of 
observation (over 3,000 patients). We used several strategies to 
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overcome these limitations. First we applied REM to strengthen the 
validity of our results in case of substantial heterogeneity among 
trials. Furthermore, we conducted a sensitivity analysis in which we 
considered only papers with a low risk of bias, namely those with 
NOS score above 6. The observed pooled effect sizes did not differ 
significantly from the overall analysis except in a few cases. Hence, 
the consistency in the direction of our findings is reliable and the 
methods were applied rigorously.  
 
Future research  
The pharmacogenomic approach to medical care is becoming a 
reality in several fields, notably for patients at a high risk of adverse 
drug reactions (Sychev and Malova, 2015). In the ART setting, a 
pharmacogenomic approach to COS could lead to better 
standardization of treatments, thereby increasing the chance of ART 
success and reducing a potentially life-threatening excessive ovarian 
response.  
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Remarkably, no large randomized clinical trial has yet been 
conducted, notwithstanding the relatively high number of studies 
published over the last 20 years. Based on existing evidence, we 
believe that the pharmacogenomic approach to COS is still a 
neglected topic in the reproductive field. Furthermore, it should be 
considered that most of polymorphisms reported in our paper are 
widespread in the general population and in women with 
reproductive disorders (Nilsson et al., 1997, Alviggi et al., 2009a, 
Alviggi et al., 2011b, Simoni and Casarini, 2014, Alviggi et al., 
2015), and that genotype analysis can now be provided at the same 
costs of other commonly used analyses (e.g. AMH, AFC). 
 
Conclusions  
Our systematic review indicates that specific SNPs of gonadotropins 
and their receptors could influence ovarian stimulation outcomes. 
This evidence is supported by a large number of trials mainly 
focused on FSHR (rs6165) and FSHR (rs6166). Our analysis showed 
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that higher FSH consumption is expected in homozygotes for the A 
allele of FSHR (rs1394205) polymorphism than allele G carriers. 
Moreover, FSHR (rs6166) GG homozygotes seem to be less 
responsive to COS treatment; in fact, they have fewer oocytes and 
require larger FSH doses per oocyte than AA and AG carriers. 
Although LHB (rs1800447) and LHCGR (rs2293275) has been 
implicated in COS outcome, their role in clinical practice remains to 
be established. It was hypothesized that the effect of these 
polymorphism on COS may partially explain the phenomenon of 
“hypo-response” that was reported in 10-15% of 
normogonadotropic ART women (Alviggi et al., 2013). This peculiar 
ovarian response profile was recently included in the new 
classification of low prognosis women (Alviggi et al., 2016a, 
Humaidan et al., 2016). Given the overall effect of gonadotropin and 
their receptor SNPs on COS, further consideration of a 
pharmacogenomic approach to COS seems justified.  
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Figures  
Figure 1A. Prevalence of follicle-stimulating hormone receptor 
(FSHR) polymorphisms: comparison between population study and 
data reported by Perez-Mayorga et al. (Perez Mayorga et al., 2000). 
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Figures 2A: Mean number of oocytes retrieved in hyporesponders 
(group A) and in controls (group B), P = .0003 
 
 
 
 
Figure 3A. Serum estradiol levels on the day of human chorionic 
gonadotrophin (hCG) administration in hyporesponders (group A) 
and in normal responders (group B). P ¼ .0001. 
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Figure 1B Allele C coexpression of FSHR -29; LHCGR 291 and 
cumulative and FSHR rs6166 r-hFSH dose/total number of oocytes 
or mature oocytes ratio. 
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Figure 1C. Study flow chart 
 
 
 
  
 
 
88 
 
Figure 2C: Forest plots evaluating the overall differences among 
FSHR (rs1394205) genotypes carriers in relation to FSH 
consumption. (A) (rs1394205) G homozygous versus A homozygous, 
(B) (rs1394205) G homozygous versus heterozygous, (C) 
(rs1394205) heterozygous versus A homozygous. 
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Figure 3C: Forest plots evaluating the differences among the FSHR 
(rs6165) genotype carriers  in relation to stimulation duration. (A) 
(rs6165) A homozygous versus G homozygous. (B) (rs6165) A 
homozygous versus heterozygous, (C) (rs6165) heterozygous versus 
G homozygous. 
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Figure 4C: Forest plots of the differences among FSHR (rs6165) 
genotype carriers in relation to the number of oocytes retrieved. (A) 
(rs6165) T (A) homozygous versus A (G) homozygous, (B) (rs6165) 
T (A) homozygous versus heterozygous, (C) (rs6165) heterozygous 
versus A (G) homozygous. 
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Figure 5C: Forest plots evaluating the overall differences among 
FSHR (rs6166) genotype carriers considering the total number of 
oocytes retrieved. (A) (rs6166) N (A) homozygous versus S (G) 
homozygous, (B) (rs6166) N (A) homozygous versus heterozygous, 
(C) (rs6166) heterozygous versus S (G) homozygous. 
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Figure 6C: Forest plots evaluating the overall differences among 
FSHR (rs6166) genotype carriers considering the total number of 
mature oocytes retrieved. (A) (rs6166) N (A) homozygous versus S 
(G) homozygous, (B) (rs6166) N (A) homozygous versus 
heterozygous, (C) (rs6166) heterozygous versus S (G) homozygous. 
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Figure 7C: Forest plots evaluating the overall differences among 
FSHR (rs6165) genotype carriers considering the ratio between the 
FSH consumption and the number of oocytes retrieved. (A) (rs6165) 
T (A) homozygous versus A (G) homozygous, (B) (rs6165) T (A) 
homozygous versus heterozygous, (C) (rs6165) heterozygous versus 
A (G) homozygous. 
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Figure 8C: Forest plots evaluating the overall differences among 
FSHR (rs6166) genotype carriers considering the ratio between the 
FSH consumption and the number of oocytes retrieved. (A) (rs6166) 
N (A) homozygous versus S (G) homozygous, (B) (rs6166) N (A) 
homozygous versus heterozygous, (C) (rs6166) heterozygous versus 
S (G) homozygous. 
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Figure 9C: Funnel plots, trim and fill and Egger test results 
considering ongoing pregnancy rate (A) (rs6166), (B) (rs6165) and 
(C) (rs1394205) 
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Figure 10C: Forest plots evaluating the overall differences between 
NN (AA) and SS (GG) carriers [FSHR (rs6166)] considering 
FSH/oocyte ratio. (A) recombinant gonadotropin (B) no-recombinant 
gonadotropin. 
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Figure 11C: Forest plots evaluating the overall differences between 
NN (AA) and SS (GG) carriers [FSHR (rs6166)] considering the 
number of oocytes retrieved oocytes retrieved (A) recombinant 
gonadotropin (B) no-recombinant gonadotropin. 
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Tables 
 
Table 1A: Characteristics of Group A and Group B patients and 
Indications for In Vitro Fertilization. 
 
 
Characteristics 
Group A, 
Hyporesponders 
(N=17) 
Group B, 
Controls 
(N=25) 
 
P Value 
Age, years 31.82 ± 4.08 29.32 ± 4.67  NS 
BMI, kg/m2 25.0 ± 3.4 23.6 ± 3.2  NS 
Years of infertility 4.15 ± 1.2 3.2 ± 0.9 .0055 
Baseline LH,IU/L 4.2 ± 1.2 4.1 ± 1.8  NS 
Baseline estradiol, pg/mL 48.75 ± 16.9 43.11 ± 19.4  NS 
Indications for IVF 
       Tubal factor (%) 
       Male factor (%) 
       Combined (%) 
       Other (%) 
 
5 (29.4) 
7 (41.2) 
3 (17.6) 
2 (11,8) 
 
5 (20) 
8 (32) 
5 (20) 
7 (28) 
 
 NS 
 NS 
 NS 
 NS 
Distribution of the FSH-R 
genotypes 
      Ser/Ser (%) 
      Asn/Ser (%) 
      Asn/Asn (%) 
 
10 (58.8) 
4 (23.5) 
3 (17.6) 
 
5 (20) 
15 (60) 
5 (20) 
 
.02 
.04 
 NS 
Abbreviations: NS, not significant; BMI, body mass index; LH, luteinizing hormone; IVF, in vitro fertilization; FSH-R, 
follicle-stimulating hormone receptor. 
aData are showed as means ± standard deviation. 
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Table 2A: Outcome of Cycles of Assisted Reproduction in Groups A 
and B. 
 
 
Characteristics 
Group A, 
Hyporesponders 
(N=17) 
Group B, 
Controls 
(N=25) 
 
P Value 
Baseline FSH 6.9 ± 1.9 5.6 ± 1.9 .035 
Baseline LH 4.2 ± 1.2 4.1 ± 1.8  NS 
Duration of stimulation, 
days 
12.7 ± 2.4 10.8 ± 2.8 .03 
N. of r-hFSH vials 36.3 ± 7.5 28.6 ± 4.5 .0002 
Estradiol on hCG day 997.8 ± 384.9 1749.1 ± 644.4 .0001 
N. oocytes retrieved 7.1 ± 1.5 9.6 ± 2.4 .0005 
N. embryo transferred 2.1 ± 0.7 2.7 ±  0.4 .001 
Implantation rate, % 11.1 16.2  NS 
Pregnancy rate, % 17.6 36.0  NS 
Rate of ongoing 
pregnancies, % 
11.7 32.0  NS 
Abbreviations: NS, not significant; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotrophin; LH, 
luteinizing hormone; r-FSH: recombinant FSH; r-hFSH, recombinant human follicle-stimulating hormone. 
aData are showed as mean ± standard deviation. 
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Table 1B: Baseline characteristics of population study. 
 
Basal characteristics  Values 
Age (years) 30.71±2.61 
BMI (kg/m2) 22.94±2.35 
AMH (ng/mL) 2.70±1.76 
Antral follicle count 12.36±3.63 
Basal FSH (IU/L) 6.73±1.98 
Basal estradiol (pg/mL) 80.65±101.16 
 
 
 
Table 2B: Treatment outcomes; continuous data are expressed as 
mean ± standard deviation; categorical data as percentage. 
 
Treatment outcomes Values 
Total FSH doses (IU) 1725.33±520.15 
Days of stimulation 11.24±1.69 
Estradiol at the day of hCG (pg/mL) 1655.43±895.59 
Follicles >10 mm 11.04±4.41 
Follicles >16 mm 7.72±3.15 
Oocytes number 9.51±3.82 
Mature oocytes number 7.78±3.39 
Oocytes inseminated 5.35±3.50 
Oocytes fertilized 3.61±2.55 
Oocytes cryopreserved 0.35±1.36 
Embryos cryopreserved 6.73±1.98 
Embryos transferred 1.65±0.80 
Cycles cancelled for hyper-response 2 (2.1%) 
OHSS 1 (1.1%) 
Pregnancy rate (beta-hCG) per cycle 42.5% 
Clinical pregnancy rate per cycle 34.0% 
Miscarriage rate per cycle 9.4% 
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Table 3B: Treatment outcomes, stratifying patients according to 
the FSHR 307 (rs6165). 
 
 homozygous 
A/A 
heterozygous 
A/G 
homozygous  
G/G 
p-
value 
Total FSH doses (IU) 1781.23+568.45 1730.04+550.19 1647.17+383.58 0.536 
FSH/oocytes 243.42+97.60 338.52+251.80 252.60+166.33 0.050 
Days of stimulation 11.13+1.68 11.35+1.82 11.10+1.41 0.769 
Endometrial 
thickness (mm) 
9.70+1.15 10.38+2.00 10.28+2.09 0.547 
Estradiol at the day 
of hCG (pg/mL) 
1555.24+663.85 1607.54+906.21 1859.42+1092.75 0.513 
Follicles ≥ 16mm 
hCG day hCG 
7.63±2.72 7.73±3.26 7.80±3.50 0.983 
Oocytes number 9.58+3.32 9.24+3.57 10.10+4.98 0.685 
Mature oocytes 
number 
8.13+2.72 7.50+3.71 8.06+3.47 0.643 
Oocytes inseminated 6.08+3.26 5.18+3.60 4.90+3.55 0.346 
Oocytes fertilized 3.92+2.53 3.60+2.66 3.25+2.38 0.537 
Oocytes 
cryopreserved 
0.21+1.02 0.36+1.44 0.50+1.54 0.802 
Embryos 
cryopreserved 
0.96+1.81 1.16+2.05 0.65+1.31 0.534 
Embryos transferred 1.63+0.77 1.56+0.79 1.90+0.85 0.236 
Implantation rate 10/39 23/77 10/38 0.795 
Pregnancy rate per 
embryo transferred 
12/39 24/77 11/38 0.867 
Ongoing pregnancy 
rate per embryo 
transferred  
9/39 21/77 9/38 0.792 
Pregnancy rate per 
cycle 
12/24 24/50 11/20 0.930 
Ongoing pregnancy 
rate per cycle 
9/24 21/50 9/20 0.863 
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Table 4B: Treatment outcomes, stratifying patients according to 
the 680 (rs6166). 
 
 homozygous 
A/A 
heterozygous 
A/G 
homozygous  
G/G 
p-
value 
Total FSH doses (IU) 1809.76+563.38 1725.25+554.53 1633.02+379.45 0.698 
FSH/oocytes 248.80+96.34 333.44+250.88 252.60+166.33 0.049 
Days of stimulation 11.42+1.72 11.23+1.81 11.50+1.40 0.804 
Endometrial 
thickness (mm) 
9.70+1.15 10.38+2.00 10.28+2.09 0.547 
Estradiol at the day 
of hCG (pg/mL) 
1624.09+722.40 1568.46+880.90 1859.42+1092.75 0.514 
Follicles ≥ 16mm 
hCG day hCG 
7.58±2.70 7.71±3.28 7.90±3.45 0.944 
Oocytes number 9.67+3.33 9.20+3.59 10.05+4.86 0.697 
Mature oocytes 
number 
8.22+2.78 7.45+3.67 8.06+3.47 0.725 
Oocytes inseminated 6.21+3.35 5.18+3.55 4.76+3.52 0.476 
Oocytes fertilized 4.04+2.56 3.57+2.65 3.19+2.38 0.694 
Oocytes 
cryopreserved 
0.21+1.02 0.37+1.45 0.48+1.50 0.779 
Embryos 
cryopreserved 
1.00+1.82 1.16+2.06 0.62+1.28 0.581 
Embryos transferred 1.63+0.77 1.55+0.79 1.90+0.83 0.273 
Implantation rate 10/37 21/77 12/40 0.844 
Pregnancy rate per 
embryo transferred 
12/37 22/77  13/40  
 
0.839 
Ongoing pregnancy 
rate per embryo 
transferred  
9/37 19/77 11/40 0.848 
Pregnancy rate per 
cycle 
12/23 23/50 13/21 0.812 
Ongoing pregnancy 
rate per cycle 
9/23 19/50 11/21 0.867 
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Table 5B: Treatment outcomes, stratifying patients according to 
the FSHR – 29 (rs1394205). 
 
 homozygous 
G/G  
heterozygous 
G/A 
homozygous 
A/A 
p-
value 
Total FSH doses (IU) 1730.04+554.55 1745.19+476.55 1601.71+487.46 0.804 
FSH/oocytes 322.78+239.49 229.73+109.79 312.83+161.03 0.186 
Days of stimulation 11.20+1.52 11.39+1.87 11.50+1.40 0.733 
Endometrial 
thickness (mm) 
10.29+2.00 9.91+1.55 10.47+1.36 0.776 
Estradiol at the day 
of hCG (pg/mL) 
1518.52+742.11 1832.04+1184.50 2039.14+706.30 0.197 
Follicles ≥ 16mm 
hCG day hCG 
8.07±3.23 6.90±2.83 8.50±3.50 0.197 
Oocytes number 9.60+3.90 9.58+3.84 8.63+3.54 0.794 
Mature oocytes 
number 
7.67+3.65 8.46+2.90 6.50+2.83 0.344 
Oocytes inseminated 5.22+3.49 5.90+3.67 4.13+2.70 0.404 
Oocytes fertilized 3.47+2.67 3.97+2.60 3.13+1.36 0.595 
Oocytes 
cryopreserved 
0.38+1.38 0.19+1.08 0.75+2.12 0.572 
Embryos 
cryopreserved 
1.05+2.03 1.03+1.72 0.50+0.76 0.730 
Embryos transferred 1.62+0.85 1.61+0.76 2.00+0.53 0.435 
Implantation rate 18/88 21/50 4/16 0.934 
Pregnancy rate per 
embryo transferred 
22/88 21/50 4/16 0.754 
Ongoing pregnancy 
rate per embryo 
transferred  
16/88 19/50 4/16 0.770 
Pregnancy rate per 
cycle 
22/55 21/31 4/8 0.879 
Ongoing pregnancy 
rate per cycle 
16/55 19/31 4/8 0.435 
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Table 6B: Treatment outcomes, stratifying patients according to 
the LHCGR 291 (rs12470652). 
 
 T/T C/T p-value 
Total FSH doses (IU) 1736.38+534.53 1568.75+196.17 0.449 
FSH/oocytes 305.86+208.66 147.65+46.77 0.069 
Days of stimulation 11.21+1.70 11.57+1.62 0.588 
Endometrial thickness 
(mm) 
9.97+1.49 11.04+2.76 0.146 
Estradiol at the day of hCG 
(pg/mL) 
1580.60+860.03 2733.00+747.23 0.005 
Follicles ≥ 16mm hCG day 
hCG 
7.80±3.16 6.71±2.98 0.382 
Oocytes number 9.28+3.81 12.43+2.82 0.035 
Mature oocytes number 7.45+3.21 11.43+3.41 0.002 
Oocytes inseminated 4.92+3.20 10.71+2.56 0.001 
Oocytes fertilized 3.24+2.16 8.14+2.91 0.001 
Oocytes cryopreserved 0.38+1.41 0.00+0.00 0.480 
Embryos cryopreserved 0.75+1.47 4.14+3.08 0.001 
Embryos transferred 1.68+0.81 1.29+0.49 0.213 
Implantation rate 41/145 2/9 0.992 
Pregnancy rate per embryo 
transferred 
45/145 4/9 0.639 
Ongoing pregnancy rate 
per embryo transferred  
37/145 2/9 0.861 
Pregnancy rate per cycle 45/87 4/7 0.907 
Ongoing pregnancy rate 
per cycle 
37/87 2/7 0.747 
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Table 1C: Characteristics of studies included in the analysis. 
 
Authors Year SNPs 
evaluated 
Country  Partecipants Mean age Study design  
NOS 
score 
Achrekar et al.  2009 FSHR 
(rs6165), 
FSHR (rs6166) 
India 50 30.09 ± 1.50 Retrospective 7 
Achrekar et al.  2009 FSHR 
(rs1394205) 
India 150 NA Retrospective 7 
Alviggi et al.  2009 LHB 
(rs1800447) 
Italy 60 30.81 ± 3.39 Retrospective 6 
Alviggi et al.  2013 LHB 
(rs1800447) 
Denmark  220 30.65 ± 3.95 Retrospective 6 
Alviggi et al.  2016 FSHR 
(rs6165), 
FSHR (rs6166) 
Italy 42 30.57 ± 4.37 Retrospective 6 
Anagnostou et 
al.  
2012 FSHR (rs6166) Greece 109 35.00 ± 4.50 Prospective 6 
Behre et al. 2005 FSHR (rs6166) Germany 93 33.10 ± 0.64 Prospective 7 
Dan et al. 2015 FSHR 
(rs1394205) 
China 158 NA Prospective 7 
Davar et al.  2014 LHB 
(rs1056917) 
Iran 220 29.94 ± 5.98 Prospective 7 
De Castro et al.  2003 FSHR (rs6165) Spain 102 33.70 ± 3.10 Retrospective 6 
Desai et al.  2011 FSHR  
(rs1394205) 
India 100 33.11 ± 0.82 Retrospective 8 
Genro et al.  2012 FSHR 
(rs6165), 
FSHR (rs6166) 
Brazil 124 34.95 ± 3.82 Prospective 8 
Huang X et al.  2015 FSHR (rs6166) China 1250 31.31 ± 3.34 Retrospective 6 
Huang S et al.  2010 FSHR (rs6166) China 136 30.33 ± 3.31 Prospective 6 
Jun et al.  2006 FSHR (rs6166) South 
Corea 
263 32.60 ± 0.40 Prospective 7 
Klinkert et al.  2006 FSHR (rs6166) Netherlands 105 36.90 ± 5.10 Prospective 6 
Laven et al.  2003 FSHR  Germany 148 28.20 ± 3.10 Prospective 6 
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(rs6165), 
FSHR (rs6166) 
Lazaros et al.  2013 FSHR  
(rs6165), 
FSHR (rs6166) 
Greece 604 NA Retrospective 6 
Lindgren et al.  2016 LHCGR 
(rs2293275) 
Denmark 384 31.92 ± 2.90 Prospective 8 
Lledo et al. 2013 FSHR (rs6166) Spain 145 25.60 ± 3.80 Retrospective 6 
Lledo et al.  2016 FSHR (rs6166) Spain 191 25.60 ± 3.90 Retrospective 6 
Loutradis et al.  2006 FSHR (rs6166) Greece 125 30.30 ± 3.00 Retrospective 5 
Mohiyiddeen et 
al. a 
2013 FSHR (rs6166) UK 212 33.17 ± 3.50 Prospective 7 
Mohiyiddeen et 
al. b 
2013 FSHR (rs6166) UK 504 33.50 ± 3.70 Prospective 7 
Nordhoff et al.  2011 FSHR (rs6166) Germany 22 32.40 ± 3.35 Retrospective 3 
Perez Mayorga 
et al.  
2000 FSHR (rs6166) Germany 161 32.60 ± 0.50 Prospective 6 
Yin et al.  2015 LHCGR 
(rs13405728) 
China 236 NA Prospective 6 
Sheikhha et al  2011 FSHR (rs6166) Iran 108 29.63 ± 4.70 Retrospective 6 
Sudo et al.  2002 FSHR (rs6166) Japan 522 31.83 ± 0.77 Retrospective 5 
Tohlob et al.  2016 FSHR 
(rs1394205) 
UK 559 33.23 ± 5.1 Retrospective 6 
Trevisan et al.  2014 FSHR 
(rs6165), 
FSHR (rs6166) 
Italy 149 NA Retrospective 5 
Yan et al.  2013 FSHR 
(rs6165), 
FSHR (rs6166) 
China 450 32.15 ± 4.96 Retrospective 6 
Zalewski et al.  2013 FSHR (rs6166) Poland 22 33.10 ± 5.00 Retrospective 3 
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Table 2C: Pooled effect estimates including only FSHR haplotypes 
with significant overall effect on ovarian stimulation outcomes. 
 
  
FSHR 
variant 
Compariso
n 
Parameter Effect size [95%CI] I2% Test for 
overall 
effect (P 
value) 
FSHR 
(rs6165)  
AA vs GG Stimulation duration -0.59 [-1.24, 0.05] 60 0.35 
Number of oocytes 1.85 [0.85, 2.85] 0 <0.01 
FSH/oocytes ratio -24.06 [-47.28, -0.84] 50 0.04 
AA vs GA Stimulation duration -0.48 [-0.87, -0.10] 44 0.01 
Number of oocytes 1.62 [0.28, 2.95] 56 0.02 
FSH/oocytes ratio -24.31 [-65.37, 16.75] 58 0.61 
GA vs GG Stimulation duration -0.29 [-0.95, 0.37] 0 0.39 
Number of oocytes -0.37 [-1.51, 0.78] 18 0.53 
FSH/oocytes ratio 14.05 [-39.59, 67.69 73 0.61 
FSHR 
(rs6166)  
 
AA vs GG Number of oocytes 0.82 [0.13, 1.51] 81 <0.01 
Number of M2 oocytes 1.03 [0.01, 2.05] 0 0.05 
FSH/oocyte ratio -45.24 [-86.62, -3.85] 93 0.03 
AA vs GA Number of oocytes 0.18 [-0.84, 0.48] 85 0.59 
Number of M2 oocytes 0.79 [-0.05, 1.62] 0 0.06 
FSH/oocyte ratio -14.84 [-42.13, 12.44] 93 0.29 
GA vs GG Number of oocytes 0.89 [0.13, 1.66] 77 0.01 
Number of M2 oocytes 0.34 [-0.57, 1.26] 49 0.46 
FSH/oocyte ratio -31.47 [-57.01, -5.93] 85 0.02 
FSHR 
(rs1394205) 
GG vs AA FSH consumption -1294.61 [593.08, 1996.14] 99 <0.01 
AA vs GA FSH consumption -1014.36 [364.11, 1664.61] 99 <0.01 
GA vs GG FSH consumption -277.84 [-589.60, 1145.28] 10
0 
0.53 
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Table 3C Worldwide distribution, pathogenic mechanism and clinical effects of SNPs significantly related to 
COS outcome 
 
Gene refSNP Che DNA 
nucleotide 
Ancestral 
allele 
Amino 
acid 
and 
allele 
Worldwide 
distribution 
Protein  Pathogenic 
mechanism 
Clinical 
effect  
FSHR rs6165 2 c.919 G>A G A = Asn 
= N 
G = Ser = 
S  
 
G allele shows 
similar 
distribution of 
rs6166 with 
exception of 
African 
population 
(African 
ancestry in 
Southwest USA, 
Kenya, Nigeria)  
T307A Greater in vivo 
resistance to FSH 
activity 
Higher FSH 
basal levels 
 
Highest 
amount of 
FSH 
required 
during COS 
FSHR rs6166 2 c.2039 G>A A A = Thr 
= T  
G = Ala = 
A  
 
G allele is highly 
prevalent in 
North-Western 
Pakistan, 
Siberia, Mato 
Grosso, (Brazil) 
and Oceania 
N680S Greater in vivo 
resistance to FSH 
activity  
Higher FSH 
basal levels 
 
Highest 
amount of 
FSH 
required 
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during COS 
FSHR rs1394205 2 c.-29 G>A G / A allele highly 
prevalent in 
African 
population and 
Japanise and 
Iberian  
population 
(Spain) 
/ A allele showed 
reduced 
transcriptional 
activity 
compared with G 
allele 
Higher 
amount of 
FSH 
required 
during COS 
In allele A 
carriers  
LHB rs1800447 19 c.82 T>C 
 
T T = Trp 
= W 
C = Arg 
= R 
 
C allele highly 
prevalent in 
Australian 
aboriginal and 
Finnish 
populations 
W8R Shorter half-life 
than wild type 
form 
Higher 
amount of 
exogenous 
FSH 
required 
during COS 
LHCGR rs2293275 2 c. 935 A>G A A = Asn 
= N  
G = Ser = 
S  
 
G allele highly 
expressed in 
Asian and 
African 
population 
N312S Impaired second 
messenger 
(cAMP) pathway 
Higher 
ongoing 
pregnancy 
rate in SS 
carriers 
 
  
110 
 
References 
 
ACHREKAR, S. K., MODI, D. N., DESAI, S. K., MANGOLI, V. S., MANGOLI, R. V. & MAHALE, S. 
D. 2009a. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with 
variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril, 
91, 432-9. 
ACHREKAR, S. K., MODI, D. N., DESAI, S. K., MANGOLI, V. S., MANGOLI, R. V. & MAHALE, S. 
D. 2009b. Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor 
polymorphism. Reprod Biomed Online, 18, 509-15. 
ALMAWI, W. Y., HUBAIL, B., AREKAT, D. Z., AL-FARSI, S. M., AL-KINDI, S. K., AREKAT, M. 
R., MAHMOOD, N. & MADAN, S. 2015. Leutinizing hormone/choriogonadotropin receptor 
and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome. J Assist 
Reprod Genet, 32, 607-14. 
ALTMÄE, S., HOVATTA, O., STAVREUS-EVERS, A. & SALUMETS, A. 2011. Genetic predictors of 
controlled ovarian hyperstimulation: Where do we stand today? Human Reproduction Update, 
17, 813-828. 
ALVIGGI, C., ANDERSEN, C. Y., BUEHLER, K., CONFORTI, A., DE PLACIDO, G., ESTEVES, S. 
C., FISCHER, R., GALLIANO, D., POLYZOS, N. P., SUNKARA, S. K., UBALDI, F. M. & 
HUMAIDAN, P. 2016a. A new more detailed stratification of low responders to ovarian 
stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril, 105, 1452-3. 
ALVIGGI, C., CLARIZIA, R., MOLLO, A., RANIERI, A. & DE PLACIDO, G. 2011a. Who needs LH 
in ovarian stimulation? Reprod Biomed Online, 22 Suppl 1, S33-41. 
ALVIGGI, C., CLARIZIA, R., PETTERSSON, K., MOLLO, A., HUMAIDAN, P., STRINA, I., 
COPPOLA, M., RANIERI, A., D'UVA, M. & DE PLACIDO, G. 2009a. Suboptimal response to 
GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online, 
18, 9-14. 
ALVIGGI, C., CLARIZIA, R., PETTERSSON, K., MOLLO, A., HUMAIDAN, P., STRINA, I., 
COPPOLA, M., RANIERI, A., D'UVA, M. & DE PLACIDO, G. 2011b. Suboptimal response to 
GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online, 
22 Suppl 1, S67-72. 
ALVIGGI, C., CONFORTI, A., CAPRIO, F., GIZZO, S., NOVENTA, M., STRINA, I., PAGANO, T., 
DE ROSA, P., CARBONE, F., COLACURCI, N. & DE PLACIDO, G. 2016b. In Estimated 
Good Prognosis Patients Could Unexpected "Hyporesponse" to Controlled Ovarian Stimulation 
be Related to Genetic Polymorphisms of FSH Receptor? Reprod Sci, 23, 1103-8. 
ALVIGGI, C., CONFORTI, A., CARIATI, F., ALFANO, S., STRINA, I., HUHTANIEMI, I. & 
HUMAIDAN, P. 2016c. Abstracts of the 32nd Annual Meeting of the European Society of 
Human Reproduction and Embryology. Human Reproduction, 31, i1-i513. 
ALVIGGI, C., CONFORTI, A. & ESTEVES, S. C. 2015. Impact of mutations and polymorphisms of 
gonadotrophins and their receptors on the outcome of controlled ovarian stimulation. Principles 
and Practice of Controlled Ovarian Stimulation in ART. 
ALVIGGI, C., CONFORTI, A., FABOZZI, F. & DE PLACIDO, G. 2009b. Ovarian stimulation for 
IVF/ICSI cycles: A pharmacogenomic approach. Medecine Therapeutique Medecine de la 
Reproduction, Gynecologie et Endocrinologie, 11, 271-277. 
ALVIGGI, C., PETTERSSON, K., LONGOBARDI, S., ANDERSEN, C. Y., CONFORTI, A., DE 
ROSA, P., CLARIZIA, R., STRINA, I., MOLLO, A., DE PLACIDO, G. & HUMAIDAN, P. 
2013. A common polymorphic allele of the LH beta-subunit gene is associated with higher 
exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive 
technology. Reprod Biol Endocrinol, 11, 51. 
ANAGNOSTOU, E., MAVROGIANNI, D., THEOFANAKIS, C., DRAKAKIS, P., BLETSA, R., 
DEMIROL, A., GURGAN, T., ANTSAKLIS, A. & LOUTRADIS, D. 2012. ESR1, ESR2 and 
FSH receptor gene polymorphisms in combination: a useful genetic tool for the prediction of 
poor responders. Curr Pharm Biotechnol, 13, 426-34. 
ASRM 1997. Revised American Society for Reproductive Medicine classification of endometriosis: 
1996. Fertil Steril, 67, 817-21. 
BEHRE, H. M., GREB, R. R., MEMPEL, A., SONNTAG, B., KIESEL, L., KALTWAßER, P., 
SELIGER, E., RÖPKE, F., GROMOLL, J., NIESCHLAG, E. & SIMONI, M. 2005. Significance 
of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone 
  
 
 
111 
 
(FSH) receptor gene for the ovarian response to FSH: A pharmacogenetic approach to controlled 
ovarian hyperstimulation. Pharmacogenetics and Genomics, 15, 451-456. 
BOUDJENAH, R., MOLINA-GOMES, D., TORRE, A., BOITRELLE, F., TAIEB, S., DOS SANTOS, 
E., WAINER, R., DE MAZANCOURT, P., SELVA, J. & VIALARD, F. 2014. Associations 
between Individual and Combined Polymorphisms of the TNF and VEGF Genes and the 
Embryo Implantation Rate in Patients Undergoing In Vitro Fertilization (IVF) Programs. PLoS 
One, 9, e108287. 
CAPALBO, A., SAGNELLA, F., APA, R., FULGHESU, A. M., LANZONE, A., MORCIANO, A., 
FARCOMENI, A., GANGALE, M. F., MORO, F., MARTINEZ, D., CIARDULLI, A., PALLA, 
C., URAS, M. L., SPETTU, F., CAPPAI, A., CARCASSI, C., NERI, G. & TIZIANO, F. D. 
2012. The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) 
confers up to 2.7-fold increased risk of polycystic ovary syndrome in a Sardinian population. 
Clin Endocrinol (Oxf), 77, 113-9. 
CASARINI, L., MORIONDO, V., MARINO, M., ADVERSI, F., CAPODANNO, F., GRISOLIA, C., LA 
MARCA, A., LA SALA, G. B. & SIMONI, M. 2014. FSHR polymorphism p.N680S mediates 
different responses to FSH in vitro. Mol Cell Endocrinol, 393, 83-91. 
CASARINI, L., SANTI, D. & MARINO, M. 2015. Impact of gene polymorphisms of gonadotropins and 
their receptors on human reproductive success. Reproduction, 150, R175-84. 
COLOGNATO, R., AIELLO, R., DULCETTI, F., RUGGERI, A. M., DE TOFFOL, S., MARCATO, L., 
IROLLO, A. M., CRISCUOLO, C., GANGALE, M. F., MAGGI, F. & SIMONI, G. 2014. A 
pharmacogenetic-driven approach for controlled ovarian hyperstimulation by FSH treatment. 
Minerva Ginecol, 66, 543-9. 
CONFORTI, A., ALFANO, S., DE ROSA, P., ALVIGGI, C. & DE PLACIDO, G. 2017. The role of 
gonadotropin polymorphisms and their receptors in assisted reproductive technologies and 
controlled ovarian stimulation: A prospective observational study. Italian Journal of 
Gynaecology and Obstetrics, 29, 15-21. 
D'ALVA, C. B., SERAFINI, P., MOTTA, E., DA FONTE KOHEK, M. B., LATRONICO, A. C. & 
MENDONCA, B. B. 2005. Absence of follicle-stimulating hormone receptor activating 
mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertility and Sterility, 
83, 1695-1699. 
DAELEMANS, C., SMITS, G., DE MAERTELAER, V., COSTAGLIOLA, S., ENGLERT, Y., 
VASSART, G. & DELBAERE, A. 2004. Prediction of severity of symptoms in iatrogenic 
ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn 
polymorphism. J Clin Endocrinol Metab, 89, 6310-5. 
DAN, W., JING, G., LIANGBIN, X., TING, Z. & YING, Z. 2015. Association of follicle stimulating 
hormone receptor promoter with ovarian response in IVF-ET patients. Iran J Reprod Med, 13, 
715-20. 
DAVAR, R., TABIBNEJAD, N., KALANTAR, S. M. & SHEIKHHA, M. H. 2014. The luteinizing 
hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled 
ovarian hyperstimulation. Iran J Reprod Med, 12, 667-72. 
DE CASTRO, F., MORÓN, F. J., MONTORO, L., GALÁN, J. J., PÉREZ- HERNÁNDEZ, D., 
SÁNCHEZ-CASAS PADILLA, E., RAMÍREZ-LORCA, R., REAL, L. M. & RUIZ, A. 2004. 
Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics, 14, 
285-293. 
DE CASTRO, F., RUIZ, R., MONTORO, L., PÉREZ-HERNÁNDEZ, D., SÁNCHEZ-CASAS 
PADILLA, E., REAL, L. M. & RUIZ, A. 2003. Role of follicle-stimulating hormone receptor 
Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertility and Sterility, 
80, 571-576. 
DE PLACIDO, G., ALVIGGI, C., PERINO, A., STRINA, I., LISI, F., FASOLINO, A., DE PALO, R., 
RANIERI, A., COLACURCI, N. & MOLLO, A. 2005. Recombinant human LH 
supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled 
ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to 
  
 
 
112 
 
rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod, 20, 390-6. 
DESAI, S. S., ACHREKAR, S. K., PARANJAPE, S. R., DESAI, S. K., MANGOLI, V. S. & MAHALE, 
S. D. 2013. Association of allelic combinations of FSHR gene polymorphisms with ovarian 
response. Reprod Biomed Online, 27, 400-6. 
DESAI, S. S., ACHREKAR, S. K., PATHAK, B. R., DESAI, S. K., MANGOLI, V. S., MANGOLI, R. 
V. & MAHALE, S. D. 2011. Follicle-stimulating hormone receptor polymorphism (G-29A) is 
associated with altered level of receptor expression in Granulosa cells. J Clin Endocrinol Metab, 
96, 2805-12. 
DEVROEY, P., FAUSER, B. C. & DIEDRICH, K. 2009. Approaches to improve the diagnosis and 
management of infertility. Hum Reprod Update, 15, 391-408. 
DUVAL, S. 2006. The Trim and Fill Method. Publication Bias in Meta-Analysis. John Wiley & Sons, 
Ltd. 
EGGER, M., DAVEY SMITH, G., SCHNEIDER, M. & MINDER, C. 1997. Bias in meta-analysis 
detected by a simple, graphical test. Bmj, 315, 629-34. 
FERLIN, A., VINANZI, C., SELICE, R., GAROLLA, A., FRIGO, A. C. & FORESTA, C. 2011. Toward 
a pharmacogenetic approach to male infertility: polymorphism of follicle-stimulating hormone 
beta-subunit promoter. Fertil Steril, 96, 1344-1349.e2. 
FERRARETTI, A. P., GIANAROLI, L., MAGLI, M. C., D'ANGELO, A., FARFALLI, V. & 
MONTANARO, N. 2004. Exogenous luteinizing hormone in controlled ovarian 
hyperstimulation for assisted reproduction techniques. Fertil Steril, 82, 1521-6. 
FERRARETTI, A. P., LA MARCA, A., FAUSER, B. C., TARLATZIS, B., NARGUND, G. & 
GIANAROLI, L. 2011. ESHRE consensus on the definition of 'poor response' to ovarian 
stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod, 26, 1616-24. 
GENRO, V. K., MATTE, U., DE CONTO, E., CUNHA-FILHO, J. S. & FANCHIN, R. 2012. Frequent 
polymorphisms of FSH receptor do not influence antral follicle responsiveness to follicle-
stimulating hormone administration as assessed by the Follicular Output RaTe (FORT). J Assist 
Reprod Genet, 29, 657-63. 
GIZZO, S., ANDRISANI, A., NOVENTA, M., MANFE, S., OLIVA, A., GANGEMI, M., NARDELLI, 
G. B. & AMBROSINI, G. 2015. Recombinant LH supplementation during IVF cycles with a 
GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the 
optimal daily dose and timing. Mol Med Rep, 12, 4219-29. 
GIZZO, S., QUARANTA, M., ANDRISANI, A., BORDIN, L., VITAGLIANO, A., ESPOSITO, F., 
VENTURELLA, R., ZICCHINA, C., GANGEMI, M. & NOVENTA, M. 2016. Serum Stem Cell 
Factor Assay in Elderly Poor Responder Patients Undergoing IVF: A New Biomarker to 
Customize Follicle Aspiration Cycle by Cycle. Reprod Sci, 23, 61-8. 
GREB, R. R., BEHRE, H. M. & SIMONI, M. 2005a. Pharmacogenetics in ovarian stimulation - current 
concepts and future options. Reprod Biomed Online, 11, 589-600. 
GREB, R. R., GRIESHABER, K., GROMOLL, J., SONNTAG, B., NIESCHLAG, E., KIESEL, L. & 
SIMONI, M. 2005b. A common single nucleotide polymorphism in exon 10 of the human 
follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of 
the menstrual cycle. J Clin Endocrinol Metab, 90, 4866-72. 
GRIGOROVA, M., PUNAB, M., POOLAMETS, O., KELGO, P., AUSMEES, K., KORROVITS, P., 
VIHLJAJEV, V. & LAAN, M. 2010. Increased Prevalance of the -211 T allele of follicle 
stimulating hormone (FSH) beta subunit promoter polymorphism and lower serum FSH in 
infertile men. J Clin Endocrinol Metab, 95, 100-8. 
HAAVISTO, A. M., PETTERSSON, K., BERGENDAHL, M., VIRKAMAKI, A. & HUHTANIEMI, I. 
1995. Occurrence and biological properties of a common genetic variant of luteinizing hormone. 
J Clin Endocrinol Metab, 80, 1257-63. 
HOOGENDOORN, B., COLEMAN, S. L., GUY, C. A., SMITH, K., BOWEN, T., BUCKLAND, P. R. 
& O'DONOVAN, M. C. 2003. Functional analysis of human promoter polymorphisms. Hum 
Mol Genet, 12, 2249-54. 
HUANG, S., YANG, J., YIN, T., XING, L. I., JIE, L. I. & XU, W. 2010. Association of gene 
  
 
 
113 
 
polymorphism of follicle stimulating hormone receptor with ovarian response in IVF cycles. 
Medical Journal of Wuhan University, 31, 334-338. 
HUANG, X., LI, L., HONG, L., ZHOU, W., SHI, H., ZHANG, H., ZHANG, Z., SUN, X. & DU, J. 2015. 
The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated 
with the ovarian response in controlled ovarian hyperstimulation. Clin Endocrinol (Oxf), 82, 
577-83. 
HUHTANIEMI, I., JIANG, M., NILSSON, C. & PETTERSSON, K. 1999. Mutations and 
polymorphisms in gonadotropin genes. Mol Cell Endocrinol, 151, 89-94. 
HUMAIDAN, P., ALVIGGI, C., FISCHER, R. & ESTEVES, S. C. 2016. The novel POSEIDON 
stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed 
marker of successful outcome. 5, 2911. 
JUN, J. K., YOON, J. S., KU, S. Y., CHOI, Y. M., HWANG, K. R., PARK, S. Y., LEE, G. H., LEE, W. 
D., KIM, S. H., KIM, J. G. & MOON, S. Y. 2006. Follicle-stimulating hormone receptor gene 
polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum 
Genet, 51, 665-70. 
KLINKERT, E. R., TE VELDE, E. R., WEIMA, S., VAN ZANDVOORT, P. M., HANSSEN, R. G., 
NILSSON, P. R., DE JONG, F. H., LOOMAN, C. W. & BROEKMANS, F. J. 2006. FSH 
receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod 
Biomed Online, 13, 687-95. 
LA MARCA, A., PAPALEO, E., ALVIGGI, C., RUVOLO, G., DE PLACIDO, G., CANDIANI, M., 
CITTADINI, E., DE MICHELE, F., MORIONDO, V., CATELLANI, V., VOLPE, A. & 
SIMONI, M. 2013. The combination of genetic variants of the FSHB and FSHR genes affects 
serum FSH in women of reproductive age. Hum Reprod, 28, 1369-74. 
LAISK-PODAR, T., KAART, T., PETERS, M. & SALUMETS, A. 2015. Genetic variants associated 
with female reproductive ageing--potential markers for assessing ovarian function and ovarian 
stimulation outcome. Reprod Biomed Online, 31, 199-209. 
LAVEN, J. S., MULDERS, A. G., SURYANDARI, D. A., GROMOLL, J., NIESCHLAG, E., FAUSER, 
B. C. & SIMONI, M. 2003. Follicle-stimulating hormone receptor polymorphisms in women 
with normogonadotropic anovulatory infertility. Fertil Steril, 80, 986-92. 
LAZAROS, L., HATZI, E., XITA, N., TAKENAKA, A., SOFIKITIS, N., ZIKOPOULOS, K. & 
GEORGIOU, I. 2013. Influence of FSHR diplotypes on ovarian response to standard 
gonadotropin stimulation for IVF/ICSI. J Reprod Med, 58, 395-401. 
LAZAROS, L. A., HATZI, E. G., PAMPORAKI, C. E., SAKALOGLOU, P. I., XITA, N. V., 
MARKOULA, S. I., STEFOS, T. I., ZIKOPOULOS, K. A. & GEORGIOU, I. A. 2012. The 
ovarian response to standard gonadotrophin stimulation depends on FSHR, SHBG and CYP19 
gene synergism. J Assist Reprod Genet, 29, 1185-91. 
LINDGREN, I., BAATH, M., UVEBRANT, K., DEJMEK, A., KJAER, L., HENIC, E., BUNGUM, M., 
BUNGUM, L., CILIO, C., LEIJONHUFVUD, I., SKOUBY, S., ANDERSEN, C. Y. & 
GIWERCMAN, Y. L. 2016. Combined assessment of polymorphisms in the LHCGR and FSHR 
genes predict chance of pregnancy after in vitro fertilization. Hum Reprod, 31, 672-83. 
LIVSHYTS, G., PODLESNAJA, S., KRAVCHENKO, S., SUDOMA, I. & LIVSHITS, L. 2009. A 
distribution of two SNPs in exon 10 of the FSHR gene among the women with a diminished 
ovarian reserve in Ukraine. J Assist Reprod Genet, 26, 29-34. 
LLEDÓ, B., DAPENA, P., ORTIZ, J. A., MORALES, R., LLACER, J. & BERNABEU, R. 2016. 
Clinical efficacy of recombinant versus highly purified follicle-stimulating hormone according 
to follicle-stimulating hormone receptor genotype. Pharmacogenetics and Genomics, 26, 288-
293. 
LLEDO, B., GUERRERO, J., TURIENZO, A., ORTIZ, J. A., MORALES, R., TEN, J., LLACER, J. & 
BERNABEU, R. 2013. Effect of follicle-stimulating hormone receptor N680S polymorphism on 
the efficacy of follicle-stimulating hormone stimulation on donor ovarian response. 
Pharmacogenet Genomics, 23, 262-8. 
LOUTRADIS, D., PATSOULA, E., MINAS, V., KOUSSIDIS, G. A., ANTSAKLIS, A., MICHALAS, S. 
  
 
 
114 
 
& MAKRIGIANNAKIS, A. 2006. FSH receptor gene polymorphisms have a role for different 
ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod 
Genet, 23, 177-84. 
MIZZI, C., DALABIRA, E., KUMUTHINI, J., DZIMIRI, N., BALOGH, I., BASAK, N., BOHM, R., 
BORG, J., BORGIANI, P., BOZINA, N., BRUCKMUELLER, H., BURZYNSKA, B., 
CARRACEDO, A., CASCORBI, I., DELTAS, C., DOLZAN, V., FENECH, A., GRECH, G., 
KASIULEVICIUS, V., KADASI, L., KUCINSKAS, V., KHUSNUTDINOVA, E., LOUKAS, 
Y. L., MACEK, M., JR., MAKUKH, H., MATHIJSSEN, R., MITROPOULOS, K., 
MITROPOULOU, C., NOVELLI, G., PAPANTONI, I., PAVLOVIC, S., SAGLIO, G., 
SETRIC, J., STOJILJKOVIC, M., STUBBS, A. P., SQUASSINA, A., TORRES, M., 
TURNOVEC, M., VAN SCHAIK, R. H., VOSKARIDES, K., WAKIL, S. M., WERK, A., DEL 
ZOMPO, M., ZUKIC, B., KATSILA, T., LEE, M. T., MOTSINGER-RIEF, A., MC LEOD, H. 
L., VAN DER SPEK, P. J. & PATRINOS, G. P. 2016. A European Spectrum of 
Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One, 11, 
e0162866. 
MOHIYIDDEEN, L. & NARDO, L. G. 2010. Single-nucleotide polymorphisms in the FSH receptor gene 
and ovarian performance: future role in IVF. Hum Fertil (Camb), 13, 72-8. 
MOHIYIDDEEN, L., NEWMAN, W. G., CERRA, C., HORNE, G., MULUGETA, B., BYERS, H., 
ROBERTS, S. A. & NARDO, L. G. 2013a. FSH receptor genotype does not predict metaphase-
II oocyte output or fertilization rates in ICSI patients. Reprod Biomed Online, 27, 305-9. 
MOHIYIDDEEN, L., NEWMAN, W. G., CERRA, C., MCBURNEY, H., MULUGETA, B., ROBERTS, 
S. A. & NARDO, L. G. 2013b. A common Asn680Ser polymorphism in the follicle-stimulating 
hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in 
patients undergoing in vitro fertilization. Fertil Steril, 99, 149-55. 
NAKAYAMA, T., KUROI, N., SANO, M., TABARA, Y., KATSUYA, T., OGIHARA, T., MAKITA, 
Y., HATA, A., YAMADA, M., TAKAHASHI, N., HIRAWA, N., UMEMURA, S., MIKI, T. & 
SOMA, M. 2006. Mutation of the follicle-stimulating hormone receptor gene 5'-untranslated 
region associated with female hypertension. Hypertension, 48, 512-8. 
NILSSON, C., PETTERSSON, K., MILLAR, R. P., COERVER, K. A., MATZUK, M. M. & 
HUHTANIEMI, I. T. 1997. Worldwide frequency of a common genetic variant of luteinizing 
hormone: an international collaborative research. International Collaborative Research Group. 
Fertil Steril, 67, 998-1004. 
NORDHOFF, V., SONNTAG, B., VON TILS, D., GOTTE, M., SCHURING, A. N., GROMOLL, J., 
REDMANN, K., CASARINI, L. & SIMONI, M. 2011. Effects of the FSH receptor gene 
polymorphism p.N680S on cAMP and steroid production in cultured primary human granulosa 
cells. Reprod Biomed Online, 23, 196-203. 
O'BRIEN, T. J., KALMIN, M. M., HARRALSON, A. F., CLARK, A. M., GINDOFF, I., SIMMENS, S. 
J., FRANKFURTER, D. & GINDOFF, P. 2013. Association between the luteinizing 
hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian 
hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol, 
11, 71. 
PATEL, V., LIN, F. J., OJO, O., RAO, S., YU, S., ZHAN, L. & TOUCHETTE, D. R. 2014. Cost-utility 
analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute 
coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada), 
12, 438. 
PATRELLI, T. S., BERRETTA, R., GIZZO, S., PEZZUTO, A., FRANCHI, L., LUKANOVIC, A., 
NARDELLI, G. B. & MODENA, A. B. 2011. CA 125 serum values in surgically treated 
endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy 
rate. Fertil Steril, 95, 393-6. 
PEREZ MAYORGA, M., GROMOLL, J., BEHRE, H. M., GASSNER, C., NIESCHLAG, E. & SIMONI, 
M. 2000. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the 
FSH receptor genotype. J Clin Endocrinol Metab, 85, 3365-9. 
  
 
 
115 
 
ROTTERDAM 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to 
polycystic ovary syndrome. Fertil Steril, 81, 19-25. 
SHEIKHHA, M. H., EFTEKHAR, M. & KALANTAR, S. M. 2011. Investigating the association 
between polymorphism of follicle-stimulating hormone receptor gene and ovarian response in 
controlled ovarian hyperstimulation. J Hum Reprod Sci, 4, 86-90. 
SIMONI, M. & CASARINI, L. 2014. Mechanisms in endocrinology: Genetics of FSH action: a 2014-
and-beyond view. Eur J Endocrinol, 170, R91-107. 
SIMONI, M., GROMOLL, J. & NIESCHLAG, E. 1997. The follicle-stimulating hormone receptor: 
biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev, 18, 739-73. 
SUDO, S., KUDO, M., WADA, S., SATO, O., HSUEH, A. J. & FUJIMOTO, S. 2002. Genetic and 
functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod, 8, 
893-9. 
SYCHEV, D. A. & MALOVA, E. U. 2015. Evidence-based pharmacogenetics: Is it possible? Int J Risk 
Saf Med, 27 Suppl 1, S97-8. 
TOHLOB, D., ABO HASHEM, E., GHAREEB, N., GHANEM, M., ELFARAHATY, R., BYERS, H., 
PEMBERTON, P., ROBERTS, S. A., NEWMAN, W. G. & MOHIYIDDEEN, L. 2016. 
Association of a promoter polymorphism in FSHR with ovarian reserve and response to ovarian 
stimulation in women undergoing assisted reproductive treatment. Reprod Biomed Online, 33, 
391-7. 
TREVISAN, C. M., PELUSO, C., CORDTS, E. B., DE OLIVEIRA, R., CHRISTOFOLINI, D. M., 
BARBOSA, C. P. & BIANCO, B. 2014. Ala307Thr and Asn680Ser polymorphisms of FSHR 
gene in human reproduction outcomes. Cell Physiol Biochem, 34, 1527-35. 
VALKENBURG, O., VAN SANTBRINK, E. J., KONIG, T. E., THEMMEN, A. P., UITTERLINDEN, 
A. G., FAUSER, B. C., LAMBALK, C. B. & LAVEN, J. S. 2015. Follicle-stimulating hormone 
receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (World 
Health Organization class 2) anovulatory subfertility. Fertil Steril, 103, 1081-1088 e3. 
WELLS, G., SHEA, B., O’CONNELL, D., PETERSON, J., WELCH, V., LOSOS, M. & TUGWELL, P. 
2004. Quality Assessment Scales for Observational Studies. Ottawa Health Research Institute  
YAN, Y., GONG, Z., ZHANG, L., LI, Y., LI, X., ZHU, L. & SUN, L. 2013. Association of follicle-
stimulating hormone receptor polymorphisms with ovarian response in Chinese women: a 
prospective clinical study. PLoS One, 8, e78138. 
YAO, Y., MA, C. H., TANG, H. L. & HU, Y. F. 2011. Influence of follicle-stimulating hormone receptor 
(FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: a 
meta-analysis. Mol Genet Metab, 103, 388-93. 
YIN, Q., LI, Y., HUANG, J. & YANG, D. 2015. [Association of rs13405728 polymorphism of LHR gene 
with slow ovarian response]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 32, 840-3. 
ZALEWSKI, G., WOLCZYNSKI, S. & CHYCZEWSKI, L. 2013. Association of rs6166 polymorphism 
with FSH receptor transcript variants and steroid production in human granulosa cell cultures. 
Syst Biol Reprod Med, 59, 191-8. 
 
